{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 268601, "items": [{"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T21:45:35Z", "timestamp": 1574113535456}, "reference-count": 0, "publisher": "The Endocrine Society", "issue": "6", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Clinical Endocrinology & Metabolism"], "published-print": {"date-parts": [[2000, 6, 1]]}, "DOI": "10.1210/jc.85.6.2234", "type": "journal-article", "created": {"date-parts": [[2004, 2, 25]], "date-time": "2004-02-25T21:56:42Z", "timestamp": 1077746202000}, "page": "2234-2238", "source": "Crossref", "is-referenced-by-count": 30, "title": ["Low-Dose Monitored Mitotane Treatment Achieves the Therapeutic Range with Manageable Side Effects in Patients with Adrenocortical Cancer"], "prefix": "10.1210", "volume": "85", "author": [{"given": "M.", "family": "Terzolo", "sequence": "first", "affiliation": []}], "member": "80", "container-title": ["Journal of Clinical Endocrinology & Metabolism"], "language": "en", "link": [{"URL": "http://press.endocrine.org/doi/full/10.1210/jcem.85.6.6619", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 2]], "date-time": "2016-12-02T22:31:03Z", "timestamp": 1480717863000}, "score": 43.673653, "issued": {"date-parts": [[2000, 6, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2000, 6, 1]]}, "issue": "6"}, "URL": "http://dx.doi.org/10.1210/jc.85.6.2234", "ISSN": ["0021-972X"], "issn-type": [{"value": "0021-972X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T03:37:02Z", "timestamp": 1574480222665}, "publisher-location": "New York, NY", "reference-count": 61, "publisher": "Springer New York", "isbn-type": [{"value": "9780387772356", "type": "print"}, {"value": "9780387772363", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2009]]}, "DOI": "10.1007/978-0-387-77236-3_22", "type": "book-chapter", "created": {"date-parts": [[2010, 11, 22]], "date-time": "2010-11-22T22:59:47Z", "timestamp": 1290466787000}, "page": "369-381", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Mitotane"], "prefix": "10.1007", "author": [{"given": "Massimo", "family": "Terzolo", "sequence": "first", "affiliation": []}, {"given": "Arianna", "family": "Ardito", "sequence": "additional", "affiliation": []}, {"given": "Barbara", "family": "Zaggia", "sequence": "additional", "affiliation": []}, {"given": "Silvia", "family": "De Francia", "sequence": "additional", "affiliation": []}, {"given": "Fulvia", "family": "Daffara", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2010, 10, 30]]}, "reference": [{"issue": "4", "key": "22_CR1", "first-page": "386", "volume": "6", "author": "S Hahner", "year": "2005", "unstructured": "Hahner S, Fassnacht M (2005) Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6(4):386\u2013394", "journal-title": "Curr Opin Investig Drugs"}, {"key": "22_CR2", "doi-asserted-by": "publisher", "first-page": "667", "DOI": "10.1677/erc.1.01029", "volume": "680", "author": "DE Schteingart", "year": "2005", "unstructured": "Schteingart DE et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 667\u2013680", "journal-title": "Endocr Relat Cancer"}, {"key": "22_CR3", "unstructured": "MICROMEDEX\u00ae Healthcare Series, Copyright \u00a9 1974\u20132009, Thomson Reuters"}, {"key": "22_CR4", "doi-asserted-by": "crossref", "first-page": "1197", "DOI": "10.1590/S0100-879X2000001000009", "volume": "33", "author": "DE Schteingart", "year": "2000", "unstructured": "Schteingart DE (2000) Conventional and novel strategies in the treatment of adrenocortical cancer. Brazilian J Med Biol Res 33:1197\u20131200", "journal-title": "Brazilian J Med Biol Res"}, {"key": "22_CR5", "doi-asserted-by": "publisher", "first-page": "127", "DOI": "10.1016/0041-008X(73)90185-3", "volume": "24", "author": "MM Hart", "year": "1973", "unstructured": "Hart MM et al (1973) The effect of isomers of DDD on the ACTH-induced steroid output, histology and ultrastructure of the dog adrenal cortex. Toxicol Appl Pharmacol 24: 127\u2013159", "journal-title": "Toxicol Appl Pharmacol"}, {"key": "22_CR6", "doi-asserted-by": "publisher", "first-page": "326", "DOI": "10.1210/endo-62-3-326", "volume": "62", "author": "C Cueto", "year": "1958", "unstructured": "Cueto C, Brown JH (1958) The chemical fractionation of an adrenocorticolytic drug. Endocrinology 62:326\u2013333", "journal-title": "Endocrinology"}, {"key": "22_CR7", "first-page": "387", "volume": "48", "author": "AA Nelson", "year": "1949", "unstructured": "Nelson AA, Woodard G (1949) Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE). Arch Pathol (Chic) 48:387\u2013394", "journal-title": "Arch Pathol (Chic)"}, {"key": "22_CR8", "first-page": "310", "volume": "15", "author": "J Nichols", "year": "1957", "unstructured": "Nichols J, Hennigar G (1957) Studies on DDD, 2,2-bis (parachlorophenyl)-1,1-dichloroethane. Exp Med Surg 15:310\u2013316", "journal-title": "Exp Med Surg"}, {"key": "22_CR9", "first-page": "127", "volume": "29", "author": "N Kaminsky", "year": "1962", "unstructured": "Kaminsky N et al (1962) Ultrastructure of adrenal cortex of the dog during treatment with DDD. J Natl Cancer Inst 29:127\u2013159", "journal-title": "J Natl Cancer Inst"}, {"key": "22_CR10", "doi-asserted-by": "publisher", "first-page": "80", "DOI": "10.1210/endo-65-1-80", "volume": "65", "author": "O Vilar", "year": "1959", "unstructured": "Vilar O, Tullner WW (1959) Effects of o,p\u2019DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex. Endocrinology 65:80\u201386", "journal-title": "Endocrinology"}, {"key": "22_CR11", "doi-asserted-by": "crossref", "first-page": "672", "DOI": "10.7326/0003-4819-53-4-672", "volume": "53", "author": "DM Bergenstal", "year": "1960", "unstructured": "Bergenstal DM et al (1960) Chemotherapy of adrenocortical cancer with o,p\u2019DDD. Ann Intern Med 53:672", "journal-title": "Ann Intern Med"}, {"key": "22_CR12", "doi-asserted-by": "publisher", "first-page": "572", "DOI": "10.1016/0002-9343(66)90219-1", "volume": "41", "author": "AM Hutter Jr", "year": "1966", "unstructured": "Hutter AM Jr, Kayhoe DE (1966) Adrenal cortical carcinoma: clinical features in 138 patients. Am J Med 41:572\u2013580", "journal-title": "Am J Med"}, {"issue": "10", "key": "22_CR13", "doi-asserted-by": "publisher", "first-page": "1109", "DOI": "10.1001/jama.223.10.1109", "volume": "223", "author": "JA Lubitz", "year": "1973", "unstructured": "Lubitz JA et al (1973 Mar 5) Mitotane use in inoperable adrenal cortical carcinoma. JAMA. 223(10):1109\u20131112", "journal-title": "JAMA."}, {"issue": "4", "key": "22_CR14", "doi-asserted-by": "crossref", "first-page": "999", "DOI": "10.1016/S0025-7125(16)32365-3", "volume": "56", "author": "DL Hoffman", "year": "1972", "unstructured": "Hoffman DL, Mattox VR (1972 Jul) Treatment of adrenocortical carcinoma with o,p\u2019-DDD. Med Clin North Am 56(4):999\u20131012", "journal-title": "Med Clin North Am"}, {"key": "22_CR15", "doi-asserted-by": "publisher", "first-page": "26", "DOI": "10.1002/1097-0142(19840101)53:1<26::AID-CNCR2820530107>3.0.CO;2-I", "volume": "53", "author": "E Boven", "year": "1984", "unstructured": "Boven E et al (1984) Complete response of metastatized adrenal cortical carcinoma with op\u2019-DDD. Case report and literature review. Cancer 53: 26\u201329", "journal-title": "Cancer"}, {"issue": "11", "key": "22_CR16", "doi-asserted-by": "publisher", "first-page": "3145", "DOI": "10.1002/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N", "volume": "72", "author": "MD Wooten", "year": "1993", "unstructured": "Wooten MD, King DK (1993) Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72(11): 3145\u20133155", "journal-title": "Cancer"}, {"key": "22_CR17", "unstructured": "WHO handbook for reporting results of cancer treatment WHO Offset Publication No 48. Geneva, 1979"}, {"key": "22_CR18", "doi-asserted-by": "publisher", "first-page": "914", "DOI": "10.1007/s00268-001-0030-7", "volume": "25", "author": "AP Dackiw", "year": "2001", "unstructured": "Dackiw AP et al (2001) Adrenal cortical carcinoma. World J Surg 25:914\u2013926", "journal-title": "World J Surg"}, {"issue": "10", "key": "22_CR19", "doi-asserted-by": "publisher", "first-page": "3119", "DOI": "10.1002/1097-0142(19930515)71:10<3119::AID-CNCR2820711037>3.0.CO;2-8", "volume": "71", "author": "R Vassilopoulou-Sellin", "year": "1993", "unstructured": "Vassilopoulou-Sellin R et al (1993) Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71(10): 3119\u20133123", "journal-title": "Cancer"}, {"key": "22_CR20", "doi-asserted-by": "publisher", "first-page": "711", "DOI": "10.1002/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.0.CO;2-W", "volume": "88", "author": "B Wajchenberg", "year": "2000", "unstructured": "Wajchenberg B et al (2000) Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88:711\u2013736", "journal-title": "Cancer"}, {"issue": "6", "key": "22_CR21", "first-page": "1006", "volume": "110", "author": "Decker", "year": "1991", "unstructured": "Decker RA et al (1991) Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110(6):1006\u20131013", "journal-title": "Surgery"}, {"key": "22_CR22", "doi-asserted-by": "publisher", "first-page": "549", "DOI": "10.1002/1097-0142(197502)35:2<549::AID-CNCR2820350239>3.0.CO;2-G", "volume": "35", "author": "RA Hajiar", "year": "1975", "unstructured": "Hajiar RA et al (1975) Adrenal cortical carcinoma: a study of 32 patients. Cancer 35: 549\u2013554", "journal-title": "Cancer"}, {"key": "22_CR23", "first-page": "909", "volume": "64", "author": "MM Haq", "year": "1980", "unstructured": "Haq MM et al (1980) Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 64: 909\u2013913", "journal-title": "Cancer Treat Rep"}, {"key": "22_CR24", "doi-asserted-by": "publisher", "first-page": "2177", "DOI": "10.1002/1097-0142(197811)42:5<2177::AID-CNCR2820420514>3.0.CO;2-X", "volume": "42", "author": "TF Hogan", "year": "1978", "unstructured": "Hogan TF et al (1978) op\u2019,DDD (mitotane) therapy for adrenal cortical carcinoma: observation on drug dosage, toxicity, and steroid replacement. Cancer 42: 2177\u20132181", "journal-title": "Cancer"}, {"key": "22_CR25", "doi-asserted-by": "publisher", "first-page": "765", "DOI": "10.1002/1097-0142(19890801)64:3<765::AID-CNCR2820640333>3.0.CO;2-I", "volume": "64", "author": "S Venkatesh", "year": "1989", "unstructured": "Venkatesh S et al (1989) Adrenal cortical carcinoma. Cancer 64: 765\u2013769", "journal-title": "Cancer"}, {"key": "22_CR26", "first-page": "232", "volume": "2", "author": "RT Grapski", "year": "1983", "unstructured": "Grapski RT et al (1983) Cisplatin chemotherapy of adrenocortical carcinoma. Proc Am Soc Clin Oncol 2: 232", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "22_CR27", "doi-asserted-by": "publisher", "first-page": "1195", "DOI": "10.1056/NEJM199004263221705", "volume": "322", "author": "JP Luton", "year": "1990", "unstructured": "Luton JP et al (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322:1195\u20132001", "journal-title": "N Engl J Med"}, {"key": "22_CR28", "first-page": "963", "volume": "112", "author": "RF Pommier", "year": "1992", "unstructured": "Pommier RF, Brennan MF (1992) An eleven-year experience with adrenocortical carcinoma. Surgery 112: 963\u2013970", "journal-title": "Surgery"}, {"key": "22_CR29", "first-page": "419", "volume": "1", "author": "MH Tattersall", "year": "1980", "unstructured": "Tattersall MH et al (1980) Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust 1:419\u2013421", "journal-title": "Med J Aust"}, {"key": "22_CR30", "doi-asserted-by": "crossref", "first-page": "257", "DOI": "10.1016/S0022-5347(17)40734-8", "volume": "141", "author": "B Bodie", "year": "1989", "unstructured": "Bodie B et al (1989) The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 141:257\u2013260", "journal-title": "J Urol"}, {"issue": "5", "key": "22_CR31", "doi-asserted-by": "publisher", "first-page": "1159", "DOI": "10.1002/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R", "volume": "88", "author": "SK Williamson", "year": "2000", "unstructured": "Williamson SK et al (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 88(5): 1159\u20131165", "journal-title": "Cancer"}, {"key": "22_CR32", "doi-asserted-by": "publisher", "first-page": "947", "DOI": "10.1038/bjc.1994.183", "volume": "69", "author": "HR Haak", "year": "1994", "unstructured": "Haak HR et al (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947\u2013951", "journal-title": "Br J Cancer"}, {"key": "22_CR33", "doi-asserted-by": "publisher", "first-page": "47", "DOI": "10.1016/0277-5379(84)90033-6", "volume": "20", "author": "H Slooten Van", "year": "1984", "unstructured": "Van Slooten H et al (1984) The treatment of adrenocortical carcinoma with o,p\u2019-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47\u201353", "journal-title": "Eur J Cancer Clin Oncol"}, {"key": "22_CR34", "doi-asserted-by": "publisher", "first-page": "1385", "DOI": "10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2", "volume": "92", "author": "E Baudin", "year": "2001", "unstructured": "Baudin E et al (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p\u2019DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385\u20131392", "journal-title": "Cancer"}, {"key": "22_CR35", "doi-asserted-by": "publisher", "first-page": "529", "DOI": "10.1677/erc.0.0060529", "volume": "6", "author": "M Seki", "year": "1999", "unstructured": "Seki M et al (1999) Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. Endocr Relat Cancer 6:529\u2013533", "journal-title": "Endocr Relat Cancer"}, {"key": "22_CR36", "doi-asserted-by": "publisher", "first-page": "2027", "DOI": "10.1210/jc.2005-2639", "volume": "91", "author": "B Allolio", "year": "2006", "unstructured": "Allolio B, Fassnacht M (2006) Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91:2027\u20132037", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "1", "key": "22_CR37", "doi-asserted-by": "publisher", "first-page": "18", "DOI": "10.1210/jcem-73-1-18", "volume": "73", "author": "SE Bates", "year": "1991", "unstructured": "Bates SE et al (1991) Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/Pglycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 73(1): 18\u201329", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "1", "key": "22_CR38", "first-page": "133", "volume": "14", "author": "R Villa", "year": "1999", "unstructured": "Villa R et al (1999) Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int J Oncol 14(1):133\u2013138", "journal-title": "Int J Oncol"}, {"issue": "9", "key": "22_CR39", "doi-asserted-by": "publisher", "first-page": "2333", "DOI": "10.1002/cncr.10487", "volume": "94", "author": "J Abraham", "year": "2002", "unstructured": "Abraham J et al (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94(9): 2333\u20132343", "journal-title": "Cancer"}, {"key": "22_CR40", "doi-asserted-by": "publisher", "first-page": "110", "DOI": "10.1111/j.1365-2265.2005.02403.x", "volume": "64", "author": "A Faggiano", "year": "2006", "unstructured": "Faggiano A et al (2006) Rapidly progressing high o,p\u2019DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol 64:110\u2013113", "journal-title": "Clin Endocrinol"}, {"issue": "6", "key": "22_CR41", "first-page": "2234", "volume": "86", "author": "M Terzolo", "year": "2000", "unstructured": "Terzolo M et al (2000) Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer J Clin Endocrin Metab 86 (6): 2234\u20132238", "journal-title": "J Clin Endocrin Metab"}, {"key": "22_CR42", "doi-asserted-by": "publisher", "first-page": "1043", "DOI": "10.1677/ERC-08-0103", "volume": "15", "author": "F Daffara", "year": "2008", "unstructured": "Daffara F et al (2008) Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 15:1043\u20131053", "journal-title": "Endocr Relat Cancer"}, {"key": "22_CR43", "doi-asserted-by": "publisher", "first-page": "51", "DOI": "10.1111/j.1365-2265.1989.tb00453.x", "volume": "31", "author": "RV Hague", "year": "1989", "unstructured": "Hague RV et al (1989) Hepatic microsomal enzyme induction and adrenal crisis due to o,p\u2019DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol 31:51\u201357", "journal-title": "Clin Endocrinol"}, {"key": "22_CR44", "doi-asserted-by": "crossref", "first-page": "1191", "DOI": "10.1590/S0100-879X2000001000008", "volume": "33", "author": "AA Kasperlik-Zaluska", "year": "2000", "unstructured": "Kasperlik-Zaluska AA (2000) Clinical results of the use of mitotane for adrenocortical carcinoma. Brazilian J Med Biol Res 33:1191\u20131196", "journal-title": "Brazilian J Med Biol Res"}, {"key": "22_CR45", "doi-asserted-by": "publisher", "first-page": "2165", "DOI": "10.1210/jc.2005-2157", "volume": "91", "author": "N Nader", "year": "2006", "unstructured": "Nader N et al (2006) Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab 91:2165\u20132170", "journal-title": "J Clin Endocrinol Metab"}, {"key": "22_CR46", "doi-asserted-by": "publisher", "first-page": "273", "DOI": "10.1046/j.1365-2265.2003.01881.x", "volume": "60", "author": "B Allolio", "year": "2004", "unstructured": "Allolio B et al (2004) Management of adrenocortical carcinoma. Clin Endocrinol 60:273\u2013287", "journal-title": "Clin Endocrinol"}, {"key": "22_CR47", "first-page": "972", "volume": "112", "author": "P Icard", "year": "1992", "unstructured": "Icard P et al (1992) Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 112: 972\u2013980", "journal-title": "Surgery"}, {"key": "22_CR48", "doi-asserted-by": "publisher", "first-page": "2587", "DOI": "10.1002/1097-0142(19950515)75:10<2587::AID-CNCR2820751028>3.0.CO;2-5", "volume": "75", "author": "AA Kasperlik-Zaluska", "year": "1995", "unstructured": "Kasperlik-Zaluska AA et al (1995) Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 75: 2587\u20132591", "journal-title": "Cancer"}, {"key": "22_CR49", "doi-asserted-by": "publisher", "first-page": "3100", "DOI": "10.1210/jc.83.9.3100", "volume": "83", "author": "G Dickstein", "year": "1998", "unstructured": "Dickstein G et al (1998) Is there a role for low doses of mitotane (o,p\u2019-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 83:3100\u20133103", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "9", "key": "22_CR50", "doi-asserted-by": "crossref", "first-page": "1142", "DOI": "10.1001/archsurg.1982.01380330010004", "volume": "117", "author": "DE Schteingart", "year": "1982", "unstructured": "Schteingart DE et al (1982 Sep) Treatment of adrenal carcinomas. Arch Surg 117(9):1142\u20131146", "journal-title": "Arch Surg"}, {"issue": "4", "key": "22_CR51", "doi-asserted-by": "publisher", "first-page": "1488", "DOI": "10.1210/jc.84.4.1488", "volume": "84", "author": "Barzon", "year": "1999", "unstructured": "Barzon L et al (1999 Apr) Comment \u2013 Is there a role for low doses of mitotane (o,p\u2019-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 84(4):1488\u20131489", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "6", "key": "22_CR52", "doi-asserted-by": "publisher", "first-page": "490", "DOI": "10.1159/000227608", "volume": "54", "author": "L Barzon", "year": "1997", "unstructured": "Barzon L et al (1997 Nov\u2013Dec) Adrenocortical carcinoma: experience in 45 patients. Oncology 54(6):490\u2013496", "journal-title": "Oncology"}, {"key": "22_CR53", "doi-asserted-by": "publisher", "first-page": "891", "DOI": "10.1007/s00268-001-0047-y", "volume": "25", "author": "P Icard", "year": "2001", "unstructured": "Icard P et al (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25: 891\u2013897", "journal-title": "World J Surg"}, {"key": "22_CR54", "doi-asserted-by": "publisher", "first-page": "2372", "DOI": "10.1056/NEJMoa063360", "volume": "356", "author": "M Terzolo", "year": "2007", "unstructured": "Terzolo M (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372\u20132380", "journal-title": "N Engl J Med"}, {"key": "22_CR55", "doi-asserted-by": "publisher", "first-page": "1256", "DOI": "10.1056/NEJMc076267", "volume": "357", "author": "J Bertherat", "year": "2007", "unstructured": "Bertherat J et al (2007) Adjuvant mitotane in adrenocortical carcinoma. Letter to the Editor. N Engl J Med 357:1256\u20131257", "journal-title": "N Engl J Med"}, {"key": "22_CR56", "doi-asserted-by": "publisher", "first-page": "2650", "DOI": "10.1210/jc.2005-2730", "volume": "91", "author": "G Abiven", "year": "2006", "unstructured": "Abiven G et al (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91:2650\u20132655", "journal-title": "J Clin Endocrinol Metab"}, {"key": "22_CR57", "first-page": "1259", "volume": "357", "author": "M Terzolo", "year": "2007", "unstructured": "Terzolo M et al (2007) Adjuvant mitotane in adrenocortical carcinoma. Letter to the editor. N Engl J Med 357:1259", "journal-title": "N Engl J Med"}, {"key": "22_CR58", "doi-asserted-by": "publisher", "first-page": "2415", "DOI": "10.1056/NEJMe078087", "volume": "356", "author": "DE Schteingart", "year": "2007", "unstructured": "Schteingart DE (2007) Adjuvant Mitotane Therapy of Adrenal Cancer \u2013 Use and Controversy. N Engl J Med 356:2415\u20132418", "journal-title": "N Engl J Med"}, {"key": "22_CR59", "doi-asserted-by": "publisher", "first-page": "1256", "DOI": "10.1056/NEJMc076267", "volume": "357", "author": "JE Lee", "year": "2007", "unstructured": "Lee JE (2007) Adjuvant mitotane in adrenocortical carcinoma. Letter to the Editor. N Engl J Med 357:1256\u20131258", "journal-title": "N Engl J Med"}, {"key": "22_CR60", "doi-asserted-by": "publisher", "first-page": "941", "DOI": "10.1200/JCO.20.4.941", "volume": "20", "author": "A Stojadinovic", "year": "2002", "unstructured": "Stojadinovic A et al (2002) Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20:941\u2013950", "journal-title": "J Clin Oncol"}, {"issue": "12", "key": "22_CR61", "first-page": "1257", "volume": "357", "author": "G Dickstein", "year": "2007", "unstructured": "Dickstein G et al (2007) Adjuvant Mitotane in Adrenocortical Carcinoma. Letter to the Editor. N Engl J Med 357(12):1257", "journal-title": "Letter to the Editor. N Engl J Med"}], "container-title": ["Adrenocortical Carcinoma"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-0-387-77236-3_22", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 22]], "date-time": "2019-03-22T10:29:11Z", "timestamp": 1553250551000}, "score": 40.866116, "issued": {"date-parts": [[2009]]}, "ISBN": ["9780387772356", "9780387772363"], "references-count": 61, "URL": "http://dx.doi.org/10.1007/978-0-387-77236-3_22", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T02:53:35Z", "timestamp": 1574304815895}, "reference-count": 10, "publisher": "The Endocrine Society", "issue": "6", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2009, 6, 1]]}, "DOI": "10.1210/jc.2009-0120", "type": "journal-article", "created": {"date-parts": [[2009, 6, 3]], "date-time": "2009-06-03T17:50:55Z", "timestamp": 1244051455000}, "page": "1879-1880", "source": "Crossref", "is-referenced-by-count": 9, "title": ["Adjuvant Mitotane for Adrenocortical Cancer\u2014Working through Uncertainty"], "prefix": "10.1210", "volume": "94", "author": [{"given": "M.", "family": "Terzolo", "sequence": "first", "affiliation": [{"name": "Department of Clinical and Biological Sciences, Internal Medicine I (M.T.), University of Turin, 10043 Orbassano, Italy"}]}, {"given": "M.", "family": "Fassnacht", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine I (M.F., B.A.), University of Wuerzburg, 97070 Wuerzburg, Germany"}]}, {"given": "G.", "family": "Ciccone", "sequence": "additional", "affiliation": [{"name": "Oncology Prevention Center (G.C.), Molinette Hospital, 10124 Turin, Italy"}]}, {"given": "B.", "family": "Allolio", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine I (M.F., B.A.), University of Wuerzburg, 97070 Wuerzburg, Germany"}]}, {"given": "A.", "family": "Berruti", "sequence": "additional", "affiliation": [{"name": "Medical Oncology (A.B.), University of Turin, 10043 Orbassano, Italy"}]}], "member": "80", "reference": [{"key": "key\n\t\t\t\t2019041113452315600_R1", "doi-asserted-by": "crossref", "first-page": "3730", "DOI": "10.1210/jc.2008-0579", "article-title": "Commentary: adjuvant mitotane for adrenocortical cancer\u2014a recurring controversy.", "volume": "93", "author": "Huang", "year": "2008", "journal-title": "J Clin Endocrinol Metab"}, {"key": "key\n\t\t\t\t2019041113452315600_R2", "doi-asserted-by": "crossref", "first-page": "2372", "DOI": "10.1056/NEJMoa063360", "article-title": "Adjuvant mitotane treatment for adrenocortical carcinoma.", "volume": "356", "author": "Terzolo", "year": "2007", "journal-title": "N Engl J Med"}, {"key": "key\n\t\t\t\t2019041113452315600_R3", "doi-asserted-by": "crossref", "first-page": "2027", "DOI": "10.1210/jc.2005-2639", "article-title": "Adrenocortical carcinoma: clinical update.", "volume": "91", "author": "Allolio", "year": "2006", "journal-title": "J Clin Endocrinol Metab"}, {"key": "key\n\t\t\t\t2019041113452315600_R4", "first-page": "386", "article-title": "Mitotane for adrenocortical carcinoma treatment.", "volume": "6", "author": "Hahner", "year": "2005", "journal-title": "Curr Opin Investig Drugs"}, {"key": "key\n\t\t\t\t2019041113452315600_R5", "doi-asserted-by": "crossref", "first-page": "2415", "DOI": "10.1056/NEJMe078087", "article-title": "Adjuvant mitotane therapy of adrenal cancer\u2014use and controversy. Editorial.", "volume": "356", "author": "Schteingart", "year": "2007", "journal-title": "N Engl J Med"}, {"key": "key\n\t\t\t\t2019041113452315600_R6", "doi-asserted-by": "crossref", "first-page": "8664", "DOI": "10.1200/JCO.2005.01.6071", "article-title": "Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.", "volume": "23", "author": "Sargent", "year": "2005", "journal-title": "J Clin Oncol"}, {"key": "key\n\t\t\t\t2019041113452315600_R7", "doi-asserted-by": "crossref", "first-page": "1043", "DOI": "10.1677/ERC-08-0103", "article-title": "Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.", "volume": "15", "author": "Daffara", "year": "2008", "journal-title": "Endocr Relat Cancer"}, {"key": "key\n\t\t\t\t2019041113452315600_R8", "doi-asserted-by": "crossref", "first-page": "110", "DOI": "10.1111/j.1365-2265.2005.02403.x", "article-title": "Rapidly progressing high o,p\u2019DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results.", "volume": "64", "author": "Faggiano", "year": "2006", "journal-title": "Clin Endocrinol (Oxf)"}, {"key": "key\n\t\t\t\t2019041113452315600_R9", "doi-asserted-by": "crossref", "first-page": "221", "DOI": "10.1097/MED.0b013e3282fdf4c0", "article-title": "Adjunctive treatment of adrenocortical carcinoma.", "volume": "15", "author": "Terzolo", "year": "2008", "journal-title": "Curr Opin Endocrinol Diabetes Obes"}, {"key": "key\n\t\t\t\t2019041113452315600_R10", "doi-asserted-by": "crossref", "first-page": "2650", "DOI": "10.1210/jc.2005-2730", "article-title": "Bioclinical features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors from a series of 202 consecutive patients.", "volume": "91", "author": "Abiven", "year": "2006", "journal-title": "J Clin Endocrinol Metab"}], "container-title": ["The Journal of Clinical Endocrinology & Metabolism"], "language": "en", "link": [{"URL": "http://academic.oup.com/jcem/article-pdf/94/6/1879/9062669/jcem1879.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 20]], "date-time": "2019-05-20T16:25:10Z", "timestamp": 1558369510000}, "score": 40.39556, "issued": {"date-parts": [[2009, 6, 1]]}, "references-count": 10, "journal-issue": {"published-print": {"date-parts": [[2009, 6, 1]]}, "issue": "6"}, "URL": "http://dx.doi.org/10.1210/jc.2009-0120", "relation": {"cites": []}, "ISSN": ["0021-972X", "1945-7197"], "issn-type": [{"value": "0021-972X", "type": "print"}, {"value": "1945-7197", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T12:49:09Z", "timestamp": 1575463749008}, "reference-count": 30, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "3", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Current Opinion in Endocrinology & Diabetes and Obesity"], "published-print": {"date-parts": [[2014, 6]]}, "DOI": "10.1097/med.0000000000000056", "type": "journal-article", "created": {"date-parts": [[2014, 4, 11]], "date-time": "2014-04-11T10:38:57Z", "timestamp": 1397212737000}, "page": "159-165", "source": "Crossref", "is-referenced-by-count": 20, "title": ["Practical treatment using mitotane for adrenocortical carcinoma"], "prefix": "10.1097", "volume": "21", "author": [{"given": "Massimo", "family": "Terzolo", "sequence": "first", "affiliation": []}, {"given": "Barbara", "family": "Zaggia", "sequence": "additional", "affiliation": []}, {"given": "Barbara", "family": "Allasino", "sequence": "additional", "affiliation": []}, {"given": "Silvia", "family": "De Francia", "sequence": "additional", "affiliation": []}], "member": "276", "container-title": ["Current Opinion in Endocrinology & Diabetes and Obesity"], "language": "en", "deposited": {"date-parts": [[2019, 8, 9]], "date-time": "2019-08-09T12:11:52Z", "timestamp": 1565352712000}, "score": 39.71528, "subtitle": [""], "issued": {"date-parts": [[2014, 6]]}, "references-count": 30, "journal-issue": {"issue": "3"}, "URL": "http://dx.doi.org/10.1097/med.0000000000000056", "ISSN": ["1752-296X"], "issn-type": [{"value": "1752-296X", "type": "print"}], "subject": ["Internal Medicine", "Nutrition and Dietetics", "Endocrinology, Diabetes and Metabolism", "Endocrinology"]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T12:54:25Z", "timestamp": 1574859265177}, "reference-count": 0, "publisher": "Bioscientifica", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["EJEA"], "DOI": "10.1530/endoabs.49.ep26", "type": "journal-article", "created": {"date-parts": [[2017, 11, 16]], "date-time": "2017-11-16T05:46:57Z", "timestamp": 1510811217000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Assessment of the hypothalamic pituitary adrenal axis in patients receiving adjuvant mitotane treatment after radical resection of adrenocortical carcinoma"], "prefix": "10.1530", "author": [{"given": "Giuseppe", "family": "Reimondo", "sequence": "first", "affiliation": []}, {"given": "Soraya", "family": "Puglisi", "sequence": "additional", "affiliation": []}, {"given": "Barbara", "family": "Zaggia", "sequence": "additional", "affiliation": []}, {"given": "Vittoria", "family": "Basile", "sequence": "additional", "affiliation": []}, {"given": "Laura", "family": "Saba", "sequence": "additional", "affiliation": []}, {"given": "Paola", "family": "Perotti", "sequence": "additional", "affiliation": []}, {"given": "Francia Silvia", "family": "De", "sequence": "additional", "affiliation": []}, {"given": "Maria Chiara", "family": "Zatelli", "sequence": "additional", "affiliation": []}, {"given": "Salvatore", "family": "Cannavo", "sequence": "additional", "affiliation": []}, {"given": "Massimo", "family": "Terzolo", "sequence": "additional", "affiliation": []}], "member": "416", "published-online": {"date-parts": [[2017, 5, 3]]}, "container-title": ["Endocrine Abstracts"], "deposited": {"date-parts": [[2017, 11, 16]], "date-time": "2017-11-16T05:54:34Z", "timestamp": 1510811674000}, "score": 34.174595, "issued": {"date-parts": [[2017, 5, 3]]}, "references-count": 0, "URL": "http://dx.doi.org/10.1530/endoabs.49.ep26", "ISSN": ["1479-6848"], "issn-type": [{"value": "1479-6848", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T06:01:08Z", "timestamp": 1574488868618}, "reference-count": 37, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "3", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Current Opinion in Endocrinology, Diabetes and Obesity"], "published-print": {"date-parts": [[2008, 6]]}, "DOI": "10.1097/med.0b013e3282fdf4c0", "type": "journal-article", "created": {"date-parts": [[2011, 1, 14]], "date-time": "2011-01-14T06:55:49Z", "timestamp": 1294988149000}, "page": "221-226", "source": "Crossref", "is-referenced-by-count": 32, "title": ["Adjunctive treatment of adrenocortical carcinoma"], "prefix": "10.1097", "volume": "15", "author": [{"given": "Massimo", "family": "Terzolo", "sequence": "first", "affiliation": []}, {"given": "Alfredo", "family": "Berruti", "sequence": "additional", "affiliation": []}], "member": "276", "container-title": ["Current Opinion in Endocrinology, Diabetes and Obesity"], "language": "en", "deposited": {"date-parts": [[2019, 6, 7]], "date-time": "2019-06-07T21:04:31Z", "timestamp": 1559941471000}, "score": 33.062744, "subtitle": [""], "issued": {"date-parts": [[2008, 6]]}, "references-count": 37, "journal-issue": {"issue": "3"}, "URL": "http://dx.doi.org/10.1097/med.0b013e3282fdf4c0", "ISSN": ["1752-296X"], "issn-type": [{"value": "1752-296X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T01:29:58Z", "timestamp": 1575422998453}, "publisher-location": "<addr-line>8401 Connecticut Avenue, Suite 900, Chevy Chase, MD 20815</addr-line> <ext-link ext-link-type=\"uri\" href=\"http://www.endo-society.org\" type=\"simple\">www.endo-society.org</ext-link>", "reference-count": 0, "publisher": "The Endocrine Society", "isbn-type": [{"value": "1936704161", "type": "print"}, {"value": "1936704633", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2013, 6]]}, "DOI": "10.1210/mtp2.9781936704637.ch7", "type": "book-chapter", "created": {"date-parts": [[2014, 1, 8]], "date-time": "2014-01-08T17:39:06Z", "timestamp": 1389202746000}, "page": "48-54", "source": "Crossref", "is-referenced-by-count": 0, "title": ["M2 \u2013 Clinical Management of Adrenocortical Carcinoma"], "prefix": "10.1210", "author": [{"given": "Massimo", "family": "Terzolo", "sequence": "first", "affiliation": []}], "member": "80", "published-online": {"date-parts": [[2013, 11, 18]]}, "container-title": ["2013 Meet-The-Professor: Endocrine Case Management"], "deposited": {"date-parts": [[2014, 5, 19]], "date-time": "2014-05-19T14:36:37Z", "timestamp": 1400510197000}, "score": 33.05699, "issued": {"date-parts": [[2013, 6]]}, "ISBN": ["1936704161", "1936704633"], "references-count": 0, "alternative-id": ["10.1210/MTP2.9781936704637.ch7", "10.1210/MTP2.9781936704637"], "URL": "http://dx.doi.org/10.1210/mtp2.9781936704637.ch7"}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T05:39:56Z", "timestamp": 1575437996269}, "reference-count": 30, "publisher": "Bioscientifica", "issue": "6", "content-domain": {"domain": ["eje.bioscientifica.com"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2019, 6]]}, "abstract": "<jats:sec>\n<jats:title>Objective</jats:title>\n<jats:p>Many patients with adrenocortical carcinoma (ACC) suffer from tumor recurrence despite radical surgery. Evidence on the post-operative use of mitotane is controversial and no predictors of response are available. We aimed to assess whether adjuvant mitotane treatment may prolong survival in patients with non-metastatic ACC following complete resection and whether ACC patients at high risk of recurrence may benefit from treatment.</jats:p>\n</jats:sec>\n<jats:sec>\n<jats:title>Design and methods</jats:title>\n<jats:p>We retrospectively reviewed data from 152 non-metastatic ACC patients followed at the San Luigi Gonzaga Hospital: 100 patients were treated with adjuvant mitotane and 52 patients were left untreated following surgery. We assessed a number of potential predictive factors of recurrence and death. Mitotane effect was explored stratifying patients by staging (stage I\u2013II vs stage III), hormone secretion (yes vs no) and Ki67 index.</jats:p>\n</jats:sec>\n<jats:sec>\n<jats:title>Results</jats:title>\n<jats:p>The non-treated group had a higher risk of recurrence (HR: 2.79, 95%CI: 1.58\u20134.91; <jats:italic>P</jats:italic>\u2009&lt;\u20090.001) than mitotane-treated group, while overall survival was not significantly different between groups. Hormone secretion, elevated Weiss score and elevated Ki67 index confer a higher risk of both recurrence and death and stage III ACC of death. Adjuvant mitotane treatment reduced significantly the risk of death in patients with elevated Ki67 index (<jats:italic>P</jats:italic>\u2009=\u20090.005) and in patients with stage III ACC (<jats:italic>P</jats:italic>\u2009=\u20090.02).</jats:p>\n</jats:sec>\n<jats:sec>\n<jats:title>Conclusions</jats:title>\n<jats:p>Adjuvant mitotane may prolong recurrence-free survival in radically resected ACC patients with acceptable toxicity and may also prolong overall survival in a subgroup of ACC patients at high risk of recurrence.</jats:p>\n</jats:sec>", "DOI": "10.1530/eje-18-0923", "type": "journal-article", "created": {"date-parts": [[2019, 4, 16]], "date-time": "2019-04-16T15:35:14Z", "timestamp": 1555428914000}, "page": "387-396", "update-policy": "http://dx.doi.org/10.1530/crossmarkpolicy-1", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence"], "prefix": "10.1530", "volume": "180", "author": [{"given": "A", "family": "Calabrese", "sequence": "first", "affiliation": []}, {"given": "V", "family": "Basile", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Puglisi", "sequence": "additional", "affiliation": []}, {"given": "P", "family": "Perotti", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Pia", "sequence": "additional", "affiliation": []}, {"given": "L", "family": "Saba", "sequence": "additional", "affiliation": []}, {"given": "P", "family": "Berchialla", "sequence": "additional", "affiliation": []}, {"given": "F", "family": "Porpiglia", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Veltri", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Volante", "sequence": "additional", "affiliation": []}, {"given": "G", "family": "Reimondo", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Berruti", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Terzolo", "sequence": "additional", "affiliation": []}], "member": "416", "reference": [{"key": "ref81", "volume": "102", "first-page": "1358", "year": "2017", "article-title": "Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma", "journal-title": "Journal of Clinical Endocrinology and Metabolism", "DOI": "10.1210/jc.2016-2894", "doi-asserted-by": "crossref"}, {"key": "ref121", "volume": "837", "first-page": "69", "year": "2006", "article-title": "A new simple HPLC method for measuring mitotane and its two principal metabolites", "journal-title": "Journal of Chromatography B", "DOI": "10.1016/j.jchromb.2006.04.005", "doi-asserted-by": "crossref"}, {"key": "ref241", "volume": "30", "first-page": "363", "year": "2016", "article-title": "Comprehensive pan-genomic characterization of adrenocortical carcinoma", "journal-title": "Cancer Cell", "DOI": "10.1016/j.ccell.2016.07.013", "doi-asserted-by": "crossref"}, {"key": "ref291", "volume": "95", "first-page": "4925", "year": "2010", "article-title": "Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers", "journal-title": "Journal of Clinical Endocrinology and Metabolism", "DOI": "10.1210/jc.2010-0803", "doi-asserted-by": "crossref"}, {"key": "ref61", "first-page": "1", "article-title": "of Practice Guidelines on the management of adrenocortical carcinoma in adults in collaboration with the European Network for the Study of Adrenal Tumors of https org", "journal-title": "European Society Endocrinology Clinical European Journal Endocrinology"}, {"key": "ref191", "volume": "100", "first-page": "841", "year": "2015", "article-title": "Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection", "journal-title": "Journal of Clinical Endocrinology and Metabolism", "DOI": "10.1210/jc.2014-3182", "doi-asserted-by": "crossref"}, {"key": "ref251", "volume": "55", "first-page": "535", "year": "2009", "article-title": "Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification", "journal-title": "Histopathology", "DOI": "10.1111/j.1365-2559.2009.03423.x", "doi-asserted-by": "crossref"}, {"key": "ref01", "volume": "49", "first-page": "2579", "year": "2013", "article-title": "Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993", "journal-title": "European Journal of Cancer", "DOI": "10.1016/j.ejca.2013.02.034", "doi-asserted-by": "crossref"}, {"key": "ref271", "volume": "27", "first-page": "4619", "year": "2009", "article-title": "Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma", "journal-title": "Journal of Clinical Oncology", "DOI": "10.1200/JCO.2008.17.2775", "doi-asserted-by": "crossref"}, {"key": "ref31", "volume": "119", "first-page": "161", "year": "1996", "article-title": "The Italian registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients", "journal-title": "Surgery", "DOI": "10.1016/S0039-6060(96)80164-4", "doi-asserted-by": "crossref"}, {"key": "ref281", "volume": "169", "first-page": "263", "year": "2013", "article-title": "Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection", "journal-title": "European Journal of Endocrinology", "DOI": "10.1530/EJE-13-0242", "doi-asserted-by": "crossref"}, {"key": "ref231", "volume": "211", "first-page": "1106", "year": "2016", "article-title": "Outcomes after resection of cortisol-secreting adrenocortical carcinoma", "journal-title": "American Journal of Surgery", "DOI": "10.1016/j.amjsurg.2015.09.020", "doi-asserted-by": "crossref"}, {"key": "ref111", "volume": "115", "first-page": "243", "year": "2009", "article-title": "Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma", "journal-title": "Cancer", "DOI": "10.1002/cncr.24030", "doi-asserted-by": "crossref"}, {"key": "ref71", "volume": "356", "first-page": "2372", "year": "2007", "article-title": "Adjuvant mitotane treatment for adrenocortical carcinoma", "journal-title": "New England Journal of Medicine", "DOI": "10.1056/NEJMoa063360", "doi-asserted-by": "crossref"}, {"key": "ref91", "volume": "222", "first-page": "480", "year": "2016", "article-title": "Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group", "journal-title": "Journal of the American College of Surgeons", "DOI": "10.1016/j.jamcollsurg.2015.12.013", "doi-asserted-by": "crossref"}, {"key": "ref221", "volume": "65", "first-page": "832", "year": "2014", "article-title": "Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer", "journal-title": "European Urology", "DOI": "10.1016/j.eururo.2013.11.006", "doi-asserted-by": "crossref"}, {"key": "ref131", "volume": "42", "first-page": "521", "year": "2012", "article-title": "Management of adjuvant mitotane therapy following resection of adrenal cancer", "journal-title": "Endocrine", "DOI": "10.1007/s12020-012-9719-7", "doi-asserted-by": "crossref"}, {"key": "ref11", "first-page": "1", "article-title": "Management of adrenal incidentalomas of Practice Guideline in collaboration with the European Network for the study of adrenal tumors of https org", "journal-title": "European Society Endocrinology Clinical European Journal Endocrinology"}, {"key": "ref211", "volume": "46", "first-page": "713", "year": "2010", "article-title": "The European Network for the study of adrenal tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation", "journal-title": "European Journal of Cancer", "DOI": "10.1016/j.ejca.2009.12.007", "doi-asserted-by": "crossref"}, {"key": "ref51", "author": "ESMO", "first-page": "201223", "article-title": "Guidelines Working Group cancer Guidelines for diagnosis treatment and follow up of https org", "journal-title": "Adrenal Clinical Practice Annals Oncology", "DOI": "10.1093/annonc/mds231", "doi-asserted-by": "publisher"}, {"key": "ref21", "volume": "104", "first-page": "358", "year": "2017", "article-title": "European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma", "journal-title": "British Journal of Surgery", "DOI": "10.1002/bjs.10414", "doi-asserted-by": "crossref"}, {"key": "ref151", "volume": "16", "first-page": "426", "year": "2015", "article-title": "Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study", "journal-title": "Lancet Oncology", "DOI": "10.1016/S1470-2045(15)70081-1", "doi-asserted-by": "crossref"}, {"key": "ref41", "volume": "15", "first-page": "221", "year": "2008", "article-title": "Adjunctive treatment of adrenocortical carcinoma", "journal-title": "Current Opinion in Endocrinology, Diabetes and Obesity", "DOI": "10.1097/MED.0b013e3282fdf4c0", "doi-asserted-by": "crossref"}, {"key": "ref141", "volume": "366", "first-page": "2189", "year": "2012", "article-title": "Combination chemotherapy in advanced adrenocortical carcinoma", "journal-title": "New England Journal of Medicine", "DOI": "10.1056/NEJMoa1200966", "doi-asserted-by": "crossref"}, {"key": "ref161", "volume": "17", "first-page": "263", "year": "2010", "article-title": "Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane", "journal-title": "Annals of Surgical Oncology", "DOI": "10.1245/s10434-009-0716-x", "doi-asserted-by": "crossref"}, {"key": "ref171", "volume": "99", "first-page": "455", "year": "2014", "article-title": "Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma", "journal-title": "Journal of Clinical Endocrinology and Metabolism", "DOI": "10.1210/jc.2013-2856", "doi-asserted-by": "crossref"}, {"key": "ref201", "volume": "30", "first-page": "872", "year": "2006", "article-title": "Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?", "journal-title": "World Journal of Surgery", "DOI": "10.1007/s00268-005-0329-x", "doi-asserted-by": "crossref"}, {"key": "ref101", "volume": "13", "first-page": "202", "year": "1989", "article-title": "Pathologic features of prognostic significance in adrenocortical carcinoma", "journal-title": "American Journal of Surgical Pathology", "DOI": "10.1097/00000478-198903000-00004", "doi-asserted-by": "crossref"}, {"key": "ref181", "volume": "356", "first-page": "2372", "year": "2007", "article-title": "Adjuvant mitotane in adrenocortical carcinoma (letter to the editor)", "journal-title": "New England Journal of Medicine", "DOI": "10.1056/NEJMoa063360", "doi-asserted-by": "crossref"}, {"key": "ref261", "volume": "55", "first-page": "49", "year": "2008", "article-title": "Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas", "journal-title": "Endocrine Journal", "DOI": "10.1507/endocrj.K07-079", "doi-asserted-by": "crossref"}], "container-title": ["European Journal of Endocrinology"], "link": [{"URL": "https://eje.bioscientifica.com/view/journals/eje/180/6/EJE-18-0923.xml", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 25]], "date-time": "2019-05-25T03:09:10Z", "timestamp": 1558753750000}, "score": 32.802372, "issued": {"date-parts": [[2019, 6]]}, "references-count": 30, "journal-issue": {"issue": "6"}, "URL": "http://dx.doi.org/10.1530/eje-18-0923", "relation": {"cites": []}, "ISSN": ["0804-4643", "1479-683X"], "issn-type": [{"value": "0804-4643", "type": "print"}, {"value": "1479-683X", "type": "electronic"}], "subject": ["Endocrinology, Diabetes and Metabolism", "Endocrinology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T16:13:22Z", "timestamp": 1575303202013}, "reference-count": 0, "publisher": "Bioscientifica", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["EJEA"], "DOI": "10.1530/endoabs.56.p116", "type": "journal-article", "created": {"date-parts": [[2018, 5, 18]], "date-time": "2018-05-18T12:48:38Z", "timestamp": 1526647718000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Outcome of adjuvant mitotane therapy in patients with adrenocortical carcinoma: the experience of San Luigi Gonzaga Hospital"], "prefix": "10.1530", "author": [{"given": "Soraya", "family": "Puglisi", "sequence": "first", "affiliation": []}, {"given": "Anna", "family": "Calabrese", "sequence": "additional", "affiliation": []}, {"given": "Vittoria", "family": "Basile", "sequence": "additional", "affiliation": []}, {"given": "Paola", "family": "Perotti", "sequence": "additional", "affiliation": []}, {"given": "Anna", "family": "Pia", "sequence": "additional", "affiliation": []}, {"given": "Paola", "family": "Berchialla", "sequence": "additional", "affiliation": []}, {"given": "Marco", "family": "Volante", "sequence": "additional", "affiliation": []}, {"given": "Giuseppe", "family": "Reimondo", "sequence": "additional", "affiliation": []}, {"given": "Massimo", "family": "Terzolo", "sequence": "additional", "affiliation": []}], "member": "416", "published-online": {"date-parts": [[2018, 5, 8]]}, "container-title": ["Endocrine Abstracts"], "deposited": {"date-parts": [[2018, 5, 18]], "date-time": "2018-05-18T12:56:01Z", "timestamp": 1526648161000}, "score": 32.512753, "issued": {"date-parts": [[2018, 5, 8]]}, "references-count": 0, "URL": "http://dx.doi.org/10.1530/endoabs.56.p116", "ISSN": ["1479-6848"], "issn-type": [{"value": "1479-6848", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T00:37:04Z", "timestamp": 1574815024167}, "reference-count": 0, "publisher": "The Endocrine Society", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2011, 6]]}, "DOI": "10.1210/endo-meetings.2011.part2.p14.p1-619", "type": "book-chapter", "created": {"date-parts": [[2016, 7, 7]], "date-time": "2016-07-07T13:37:54Z", "timestamp": 1467898674000}, "page": "P1-619-P1-619", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Etoposide, Doxorubicin, Cisplatin, and Mitotanevs.Streptozotocin and Mitotane in Adrenocortical Carcinoma \u2014 (Preliminary) Results of the FIRM-ACT Trial"], "prefix": "10.1210", "author": [{"given": "Martin", "family": "Fassnacht", "sequence": "first", "affiliation": []}, {"given": "Massimo", "family": "Terzolo", "sequence": "additional", "affiliation": []}, {"given": "Bruno", "family": "Allolio", "sequence": "additional", "affiliation": []}, {"given": "Eric", "family": "Baudin", "sequence": "additional", "affiliation": []}, {"given": "Harm", "family": "Haak", "sequence": "additional", "affiliation": []}, {"given": "Alfredo", "family": "Berruti", "sequence": "additional", "affiliation": []}, {"given": "Kerstin", "family": "Balthasar", "sequence": "additional", "affiliation": []}, {"given": "Hans-Helge", "family": "Mueller", "sequence": "additional", "affiliation": []}, {"given": "Britt", "family": "Skogseid", "sequence": "additional", "affiliation": []}], "member": "80", "published-online": {"date-parts": [[2016, 7, 7]]}, "container-title": ["The Endocrine Society's 93rd Annual Meeting & Expo, June 4\u20137, 2011 - Boston", "CLINICAL/TRANSLATIONAL - Adrenocortical Carcinoma"], "deposited": {"date-parts": [[2016, 7, 7]], "date-time": "2016-07-07T13:37:57Z", "timestamp": 1467898677000}, "score": 32.472565, "issued": {"date-parts": [[2011, 6]]}, "references-count": 0, "alternative-id": ["10.1210/endo-meetings.2011.PART2.P14.P1-619", "10.1210/endo-meetings.2011", "10.1210/endo-meetings.2011.PART2.P14"], "URL": "http://dx.doi.org/10.1210/endo-meetings.2011.part2.p14.p1-619"}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T14:48:17Z", "timestamp": 1575211697128}, "reference-count": 0, "publisher": "Bioscientifica", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["EJEA"], "DOI": "10.1530/endoabs.32.p516", "type": "journal-article", "created": {"date-parts": [[2013, 4, 17]], "date-time": "2013-04-17T13:39:58Z", "timestamp": 1366205998000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma"], "prefix": "10.1530", "author": [{"given": "Thomas", "family": "Kerkhofs", "sequence": "first", "affiliation": []}, {"given": "Eric", "family": "Baudin", "sequence": "additional", "affiliation": []}, {"given": "Massimo", "family": "Terzolo", "sequence": "additional", "affiliation": []}, {"given": "Bruno", "family": "Allolio", "sequence": "additional", "affiliation": []}, {"given": "Rita", "family": "Chadarevian", "sequence": "additional", "affiliation": []}, {"given": "Sophie", "family": "Leboulleux", "sequence": "additional", "affiliation": []}, {"given": "Franco", "family": "Mantero", "sequence": "additional", "affiliation": []}, {"given": "Harm", "family": "Haak", "sequence": "additional", "affiliation": []}, {"given": "Martin", "family": "Fassnacht", "sequence": "additional", "affiliation": []}], "member": "416", "published-online": {"date-parts": [[2013, 4, 1]]}, "container-title": ["Endocrine Abstracts"], "deposited": {"date-parts": [[2013, 4, 17]], "date-time": "2013-04-17T13:43:31Z", "timestamp": 1366206211000}, "score": 32.153378, "issued": {"date-parts": [[2013, 4, 1]]}, "references-count": 0, "URL": "http://dx.doi.org/10.1530/endoabs.32.p516", "ISSN": ["1479-6848"], "issn-type": [{"value": "1479-6848", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T08:27:04Z", "timestamp": 1574497624035}, "reference-count": 0, "publisher": "F1000 Research Ltd", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2011, 10, 7]]}, "DOI": "10.3410/f.13335958.14702057", "type": "dataset", "created": {"date-parts": [[2012, 8, 20]], "date-time": "2012-08-20T12:21:28Z", "timestamp": 1345465288000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Faculty of 1000 evaluation for Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database."], "prefix": "10.3410", "author": [{"given": "Massimo", "family": "Terzolo", "sequence": "first", "affiliation": []}], "member": "2560", "content-created": {"date-parts": [[2011, 10, 5]]}, "container-title": ["F1000 - Post-publication peer review of the biomedical literature"], "deposited": {"date-parts": [[2012, 8, 20]], "date-time": "2012-08-20T12:22:01Z", "timestamp": 1345465321000}, "score": 30.789856, "issued": {"date-parts": [[2011, 10, 5]]}, "references-count": 0, "URL": "http://dx.doi.org/10.3410/f.13335958.14702057"}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T05:46:29Z", "timestamp": 1574142389302}, "reference-count": 32, "publisher": "Wiley", "issue": "10", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 6134, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer"], "published-print": {"date-parts": [[1998, 11, 15]]}, "DOI": "10.1002/(sici)1097-0142(19981115)83:10<2194::aid-cncr19>3.0.co;2-3", "type": "journal-article", "created": {"date-parts": [[2004, 10, 26]], "date-time": "2004-10-26T16:23:20Z", "timestamp": 1098807800000}, "page": "2194-2200", "source": "Crossref", "is-referenced-by-count": 33, "title": ["Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma"], "prefix": "10.1002", "volume": "83", "author": [{"name": "Italian Group for the Study of Adrenal Cancer", "sequence": "first", "affiliation": []}, {"given": "Alfredo", "family": "Berruti", "sequence": "additional", "affiliation": []}, {"given": "Massimo", "family": "Terzolo", "sequence": "additional", "affiliation": []}, {"given": "Anna", "family": "Pia", "sequence": "additional", "affiliation": []}, {"given": "Alberto", "family": "Angeli", "sequence": "additional", "affiliation": []}, {"given": "Luigi", "family": "Dogliotti", "sequence": "additional", "affiliation": []}], "member": "311", "reference": [{"key": "BIB1", "author": "Crucitti", "volume": "119", "first-page": "161", "year": "1996", "journal-title": "Surgery", "DOI": "10.1016/S0039-6060(96)80164-4", "doi-asserted-by": "crossref"}, {"key": "BIB2", "author": "Dogliotti", "volume": "20", "first-page": "105", "year": "1995", "journal-title": "Minerva Endocrinol"}, {"key": "BIB3", "author": "Luton", "volume": "322", "first-page": "1195", "year": "1990", "journal-title": "N Engl J Med", "DOI": "10.1056/NEJM199004263221705", "doi-asserted-by": "crossref"}, {"key": "BIB4", "author": "Bodie", "volume": "141", "first-page": "257", "year": "1989", "journal-title": "J Urol", "DOI": "10.1016/S0022-5347(17)40734-8", "doi-asserted-by": "crossref"}, {"key": "BIB5", "author": "Wooten", "volume": "72", "first-page": "3145", "year": "1993", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N", "doi-asserted-by": "crossref"}, {"key": "BIB6", "author": "Haak", "volume": "69", "first-page": "947", "year": "1994", "journal-title": "Br J Cancer", "DOI": "10.1038/bjc.1994.183", "doi-asserted-by": "crossref"}, {"key": "BIB7", "author": "Decker", "volume": "11", "first-page": "1006", "year": "1991", "journal-title": "Surgery"}, {"key": "BIB8", "author": "Tattersall", "volume": "1", "first-page": "419", "year": "1980", "journal-title": "Med J Aust"}, {"key": "BIB9", "author": "Chun", "volume": "67", "first-page": "513", "year": "1983", "journal-title": "Cancer Treat Rep"}, {"key": "BIB10", "author": "Schlumberger", "volume": "67", "first-page": "2997", "year": "1991", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(19910615)67:12<2997::AID-CNCR2820671211>3.0.CO;2-#", "doi-asserted-by": "crossref"}, {"key": "BIB11", "author": "van Slooten", "volume": "67", "first-page": "377", "year": "1983", "journal-title": "Cancer Treat Rep"}, {"key": "BIB12", "author": "Hesketh", "volume": "71", "first-page": "222", "year": "1986", "journal-title": "Cancer Treat Rep"}, {"key": "BIB13", "author": "Burgess", "volume": "12", "first-page": "188", "year": "1993", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "BIB14", "author": "Flynn", "volume": "112", "first-page": "981", "year": "1992", "journal-title": "Surgery"}, {"key": "BIB15", "author": "Bates", "volume": "73", "first-page": "18", "year": "1991", "journal-title": "J Clin Endocrinol Metab", "DOI": "10.1210/jcem-73-1-18", "doi-asserted-by": "crossref"}, {"key": "BIB16", "author": "Bukowsky", "volume": "11", "first-page": "161", "year": "1993", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1993.11.1.161", "doi-asserted-by": "crossref"}, {"key": "BIB17", "author": "Teicher", "volume": "30A", "first-page": "1411", "year": "1994", "journal-title": "Eur J Cancer", "DOI": "10.1016/0959-8049(94)00265-7", "doi-asserted-by": "crossref"}, {"key": "BIB18", "author": "Oken", "volume": "5", "first-page": "649", "year": "1982", "journal-title": "Am J Clin Oncol (CCT)", "DOI": "10.1097/00000421-198212000-00014", "doi-asserted-by": "crossref"}, {"key": "BIB19", "volume": "48", "year": "1979", "unstructured": "WHO handbook for reporting results of cancer treatment. WHO offset publication no. 48. Geneva: World Health Organization, 1979.", "series-title": "WHO offset pu", "volume-title": "WHO handbook for reporting results of cancer treatment"}, {"key": "BIB20", "author": "Preusser", "volume": "7", "first-page": "1310", "year": "1989", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1989.7.9.1310", "doi-asserted-by": "crossref"}, {"key": "BIB21", "author": "Berruti", "volume": "78", "first-page": "345", "year": "1992", "journal-title": "Tumori", "DOI": "10.1177/030089169207800512", "doi-asserted-by": "crossref"}, {"key": "BIB22", "author": "Pia", "volume": "6", "first-page": "509", "year": "1995", "journal-title": "Ann Oncol", "DOI": "10.1093/oxfordjournals.annonc.a059224", "doi-asserted-by": "crossref"}, {"key": "BIB23", "author": "Roila", "volume": "53", "first-page": "65", "year": "1996", "journal-title": "Oncology", "DOI": "10.1159/000227643", "doi-asserted-by": "crossref"}, {"key": "BIB24", "author": "Lanser", "volume": "5", "first-page": "70", "year": "1982", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "BIB25", "author": "van Slooten", "volume": "10", "first-page": "1504", "year": "1992", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1992.10.9.1504", "doi-asserted-by": "crossref"}, {"key": "BIB26", "author": "van Slooten", "volume": "20", "first-page": "57", "year": "1984", "journal-title": "Eur J Cancer Clin Oncol", "DOI": "10.1016/0277-5379(84)90033-6", "doi-asserted-by": "crossref"}, {"key": "BIB27", "author": "Vassilopoulu Sellin", "volume": "23", "first-page": "619", "year": "1991", "journal-title": "Horm Metab Res", "DOI": "10.1055/s-2007-1003770", "doi-asserted-by": "crossref"}, {"key": "BIB28", "author": "Maher", "volume": "84", "first-page": "671", "year": "1992", "journal-title": "Q J Med"}, {"key": "BIB29", "author": "Gebhardt", "volume": "29", "first-page": "331", "year": "1992", "journal-title": "Cancer Chemother Pharmacol", "DOI": "10.1007/BF00685956", "doi-asserted-by": "crossref"}, {"key": "BIB30", "author": "Freeman", "volume": "7", "first-page": "204", "year": "1986", "journal-title": "Endocr Rev", "DOI": "10.1210/edrv-7-2-204", "doi-asserted-by": "crossref"}, {"key": "BIB31", "author": "van Seters", "volume": "124", "first-page": "526", "year": "1991", "journal-title": "Acta Endocrinol", "DOI": "10.1530/acta.0.1240526", "doi-asserted-by": "crossref"}, {"key": "BIB32", "author": "Robinson", "volume": "27", "first-page": "437", "year": "1987", "journal-title": "Clin Endocrinol", "DOI": "10.1111/j.1365-2265.1987.tb01171.x", "doi-asserted-by": "crossref"}], "container-title": ["Cancer"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F(SICI)1097-0142(19981115)83:10%3C2194::AID-CNCR19%3E3.0.CO;2-3", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/(SICI)1097-0142(19981115)83:10%3C2194::AID-CNCR19%3E3.0.CO;2-3", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 11, 3]], "date-time": "2018-11-03T04:40:21Z", "timestamp": 1541220021000}, "score": 30.067213, "issued": {"date-parts": [[1998, 11, 15]]}, "references-count": 32, "journal-issue": {"published-print": {"date-parts": [[1998, 11, 15]]}, "issue": "10"}, "URL": "http://dx.doi.org/10.1002/(sici)1097-0142(19981115)83:10<2194::aid-cncr19>3.0.co;2-3", "relation": {"cites": []}, "ISSN": ["0008-543X", "1097-0142"], "issn-type": [{"value": "0008-543X", "type": "print"}, {"value": "1097-0142", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T19:41:33Z", "timestamp": 1574106093383}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1995, 11, 1]], "date-time": "1995-11-01T00:00:00Z", "timestamp": 815184000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[1995, 11]]}, "DOI": "10.1016/0959-8049(95)96213-w", "type": "journal-article", "created": {"date-parts": [[2002, 10, 21]], "date-time": "2002-10-21T14:10:42Z", "timestamp": 1035209442000}, "page": "S200-S201", "source": "Crossref", "is-referenced-by-count": 0, "title": ["964 Association of mitotane to etoposide, adriamycin and cisplatin combination chemotherapy in advanced adrenocortical carcinoma (ACC)"], "prefix": "10.1016", "volume": "31", "author": [{"given": "A.", "family": "Berruti", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Pia", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Terzolo", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Letizia", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Dogliotti", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Angeli", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:095980499596213W?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:095980499596213W?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 17]], "date-time": "2019-04-17T10:58:59Z", "timestamp": 1555498739000}, "score": 29.836445, "issued": {"date-parts": [[1995, 11]]}, "references-count": 0, "alternative-id": ["095980499596213W"], "URL": "http://dx.doi.org/10.1016/0959-8049(95)96213-w", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T11:42:15Z", "timestamp": 1574768535256}, "reference-count": 28, "publisher": "The Endocrine Society", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2017, 4, 1]]}, "DOI": "10.1210/jc.2016-2894", "type": "journal-article", "created": {"date-parts": [[2017, 4, 6]], "date-time": "2017-04-06T21:27:40Z", "timestamp": 1491514060000}, "page": "1358-1365", "source": "Crossref", "is-referenced-by-count": 27, "title": ["Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma"], "prefix": "10.1210", "volume": "102", "author": [{"given": "Alfredo", "family": "Berruti", "sequence": "first", "affiliation": []}, {"given": "Salvatore", "family": "Grisanti", "sequence": "additional", "affiliation": []}, {"given": "Alina", "family": "Pulzer", "sequence": "additional", "affiliation": []}, {"given": "M\u00e9lanie", "family": "Claps", "sequence": "additional", "affiliation": []}, {"given": "Fulvia", "family": "Daffara", "sequence": "additional", "affiliation": []}, {"given": "Paola", "family": "Loli", "sequence": "additional", "affiliation": []}, {"given": "Massimo", "family": "Mannelli", "sequence": "additional", "affiliation": []}, {"given": "Marco", "family": "Boscaro", "sequence": "additional", "affiliation": []}, {"given": "Emanuela", "family": "Arvat", "sequence": "additional", "affiliation": []}, {"given": "Guido", "family": "Tiberio", "sequence": "additional", "affiliation": []}, {"given": "Stefanie", "family": "Hahner", "sequence": "additional", "affiliation": []}, {"given": "Barbara", "family": "Zaggia", "sequence": "additional", "affiliation": []}, {"given": "Francesco", "family": "Porpiglia", "sequence": "additional", "affiliation": []}, {"given": "Marco", "family": "Volante", "sequence": "additional", "affiliation": []}, {"given": "Martin", "family": "Fassnacht", "sequence": "additional", "affiliation": []}, {"given": "Massimo", "family": "Terzolo", "sequence": "additional", "affiliation": []}], "member": "80", "published-online": {"date-parts": [[2017, 1, 11]]}, "reference": [{"key": "key\n\t\t\t\t20170406140018_B1", "volume": "23", "first-page": "131", "year": "2012", "article-title": "on behalf of the ESMO Guidelines working group. Adrenal cancer: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up", "journal-title": "Ann Oncol"}, {"issue": "8", "key": "key\n\t\t\t\t20170406140018_B2", "doi-asserted-by": "crossref", "first-page": "719", "DOI": "10.1007/s10434-999-0719-7", "article-title": "Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma", "volume": "6", "year": "1999", "journal-title": "Ann Surg Oncol"}, {"issue": "7", "key": "key\n\t\t\t\t20170406140018_B3", "doi-asserted-by": "crossref", "first-page": "891", "DOI": "10.1007/s00268-001-0047-y", "article-title": "Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group", "volume": "25", "year": "2001", "journal-title": "World J Surg"}, {"issue": "2", "key": "key\n\t\t\t\t20170406140018_B4", "doi-asserted-by": "crossref", "first-page": "243", "DOI": "10.1002/cncr.24030", "article-title": "Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification", "volume": "115", "author": "German Adrenocortical Carcinoma Registry Group", "year": "2009", "journal-title": "Cancer"}, {"issue": "23", "key": "key\n\t\t\t\t20170406140018_B5", "doi-asserted-by": "crossref", "first-page": "2372", "DOI": "10.1056/NEJMoa063360", "article-title": "Adjuvant mitotane treatment for adrenocortical carcinoma", "volume": "356", "year": "2007", "journal-title": "N Engl J Med"}, {"issue": "10", "key": "key\n\t\t\t\t20170406140018_B6", "doi-asserted-by": "crossref", "first-page": "3730", "DOI": "10.1210/jc.2008-0579", "article-title": "Adjuvant mitotane for adrenocortical cancer: a recurring controversy", "volume": "93", "year": "2008", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "6", "key": "key\n\t\t\t\t20170406140018_B7", "first-page": "2234", "article-title": "Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer", "volume": "85", "year": "2000", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "9", "key": "key\n\t\t\t\t20170406140018_B8", "doi-asserted-by": "crossref", "first-page": "1142", "DOI": "10.1001/archsurg.1982.01380330010004", "article-title": "Treatment of adrenal carcinomas", "volume": "117", "year": "1982", "journal-title": "Arch Surg"}, {"issue": "3", "key": "key\n\t\t\t\t20170406140018_B9", "doi-asserted-by": "crossref", "first-page": "765", "DOI": "10.1002/1097-0142(19890801)64:3<765::AID-CNCR2820640333>3.0.CO;2-I", "article-title": "Adrenal cortical carcinoma", "volume": "64", "year": "1989", "journal-title": "Cancer"}, {"issue": "2", "key": "key\n\t\t\t\t20170406140018_B10", "doi-asserted-by": "crossref", "first-page": "257", "DOI": "10.1016/S0022-5347(17)40734-8", "article-title": "The Cleveland Clinic experience with adrenal cortical carcinoma", "volume": "141", "year": "1989", "journal-title": "J Urol"}, {"issue": "6", "key": "key\n\t\t\t\t20170406140018_B11", "first-page": "963", "article-title": "An eleven-year experience with adrenocortical carcinoma", "volume": "112", "year": "1992", "journal-title": "Surgery"}, {"issue": "10", "key": "key\n\t\t\t\t20170406140018_B12", "doi-asserted-by": "crossref", "first-page": "3119", "DOI": "10.1002/1097-0142(19930515)71:10<3119::AID-CNCR2820711037>3.0.CO;2-8", "article-title": "Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer", "volume": "71", "year": "1993", "journal-title": "Cancer"}, {"issue": "5", "key": "key\n\t\t\t\t20170406140018_B13", "doi-asserted-by": "crossref", "first-page": "947", "DOI": "10.1038/bjc.1994.183", "article-title": "Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients", "volume": "69", "year": "1994", "journal-title": "Br J Cancer"}, {"issue": "6", "key": "key\n\t\t\t\t20170406140018_B14", "doi-asserted-by": "crossref", "first-page": "490", "DOI": "10.1159/000227608", "article-title": "Adrenocortical carcinoma: experience in 45 patients", "volume": "54", "year": "1997", "journal-title": "Oncology"}, {"issue": "9", "key": "key\n\t\t\t\t20170406140018_B15", "first-page": "3100", "article-title": "Is there a role for low doses of mitotane (o,p\u2032-DDD) as adjuvant therapy in adrenocortical carcinoma?", "volume": "83", "year": "1998", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "10", "key": "key\n\t\t\t\t20170406140018_B16", "doi-asserted-by": "crossref", "first-page": "1191", "DOI": "10.1590/S0100-879X2000001000008", "article-title": "Clinical results of the use of mitotane for adrenocortical carcinoma", "volume": "33", "year": "2000", "journal-title": "Braz J Med Biol Res"}, {"issue": "6", "key": "key\n\t\t\t\t20170406140018_B17", "doi-asserted-by": "crossref", "first-page": "1385", "DOI": "10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2", "article-title": "Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p\u2019DDD) levels on the treatment of patients with adrenocortical carcinoma", "volume": "92", "year": "2001", "journal-title": "Cancer"}, {"issue": "12", "key": "key\n\t\t\t\t20170406140018_B18", "doi-asserted-by": "crossref", "first-page": "1256", "DOI": "10.1056/NEJMc076267", "article-title": "Adjuvant mitotane in adrenocortical carcinoma", "volume": "357", "year": "2007", "journal-title": "N Engl J Med"}, {"issue": "1", "key": "key\n\t\t\t\t20170406140018_B19", "doi-asserted-by": "crossref", "first-page": "263", "DOI": "10.1245/s10434-009-0716-x", "article-title": "Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane", "volume": "17", "year": "2010", "journal-title": "Ann Surg Oncol"}, {"issue": "11", "key": "key\n\t\t\t\t20170406140018_B20", "doi-asserted-by": "crossref", "first-page": "4925", "DOI": "10.1210/jc.2010-0803", "article-title": "Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers", "volume": "95", "author": "German ACC Registry Group", "year": "2010", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "1", "key": "key\n\t\t\t\t20170406140018_B21", "doi-asserted-by": "crossref", "first-page": "265", "DOI": "10.1677/ERC-09-0190", "article-title": "The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane", "volume": "17", "year": "2010", "journal-title": "Endocr Relat Cancer"}, {"issue": "2", "key": "key\n\t\t\t\t20170406140018_B22", "doi-asserted-by": "crossref", "first-page": "455", "DOI": "10.1210/jc.2013-2856", "article-title": "Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma", "volume": "99", "year": "2014", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "4", "key": "key\n\t\t\t\t20170406140018_B23", "doi-asserted-by": "crossref", "first-page": "480", "DOI": "10.1016/j.jamcollsurg.2015.12.013", "article-title": "Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group", "volume": "222", "year": "2016", "journal-title": "J Am Coll Surg"}, {"issue": "23", "key": "key\n\t\t\t\t20170406140018_B24", "doi-asserted-by": "crossref", "first-page": "e401", "DOI": "10.1200/JCO.2009.27.5958", "article-title": "Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel", "volume": "28", "year": "2010", "journal-title": "J Clin Oncol"}, {"issue": "1", "key": "key\n\t\t\t\t20170406140018_B25", "doi-asserted-by": "crossref", "first-page": "78", "DOI": "10.6004/jnccn.2015.0011", "article-title": "Freedman-Cass D; National comprehensive cancer network. Neuroendocrine tumors, version 1.2015", "volume": "13", "year": "2015", "journal-title": "J Natl Compr Canc Netw"}, {"issue": "6", "key": "key\n\t\t\t\t20170406140018_B26", "doi-asserted-by": "crossref", "first-page": "1212", "DOI": "10.1016/S0039-6060(97)90229-4", "article-title": "Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma", "volume": "122", "year": "1997", "journal-title": "Surgery"}, {"issue": "1", "key": "key\n\t\t\t\t20170406140018_B27", "doi-asserted-by": "crossref", "first-page": "181", "DOI": "10.1210/jc.2012-2559", "article-title": "The role of surgery in the management of recurrent adrenocortical carcinoma", "volume": "98", "author": "German Adrenocortical Carcinoma Study Group", "year": "2013", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "4", "key": "key\n\t\t\t\t20170406140018_B28", "doi-asserted-by": "crossref", "first-page": "832", "DOI": "10.1016/j.eururo.2013.11.006", "article-title": "Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer", "volume": "65", "year": "2014", "journal-title": "Eur Urol"}], "container-title": ["The Journal of Clinical Endocrinology & Metabolism"], "language": "en", "deposited": {"date-parts": [[2019, 9, 20]], "date-time": "2019-09-20T18:55:31Z", "timestamp": 1569005731000}, "score": 29.6543, "issued": {"date-parts": [[2017, 1, 11]]}, "references-count": 28, "journal-issue": {"published-online": {"date-parts": [[2017, 1, 11]]}, "published-print": {"date-parts": [[2017, 4, 1]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.1210/jc.2016-2894", "relation": {"cites": []}, "ISSN": ["0021-972X", "1945-7197"], "issn-type": [{"value": "0021-972X", "type": "print"}, {"value": "1945-7197", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T01:40:04Z", "timestamp": 1574473204985}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "12", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2012, 6, 15]]}, "DOI": "10.1158/1078-0432.ccr-11-2692", "type": "journal-article", "created": {"date-parts": [[2012, 5, 1]], "date-time": "2012-05-01T04:32:00Z", "timestamp": 1335846720000}, "page": "3452-3461", "source": "Crossref", "is-referenced-by-count": 35, "title": ["Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer"], "prefix": "10.1158", "volume": "18", "author": [{"given": "M.", "family": "Volante", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Terzolo", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Fassnacht", "sequence": "additional", "affiliation": []}, {"given": "I.", "family": "Rapa", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Germano", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Sbiera", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Daffara", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Sperone", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Scagliotti", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Allolio", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Papotti", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Berruti", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2012, 4, 30]]}, "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-11-2692", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T11:56:54Z", "timestamp": 1482494214000}, "score": 29.541697, "issued": {"date-parts": [[2012, 4, 30]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2012, 6, 14]]}, "published-print": {"date-parts": [[2012, 6, 15]]}, "issue": "12"}, "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-11-2692", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T05:26:47Z", "timestamp": 1574141207608}, "reference-count": 5, "publisher": "Wiley", "issue": "7", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 6909, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer"], "published-print": {"date-parts": [[1996, 10, 1]]}, "DOI": "10.1002/(sici)1097-0142(19961001)78:7<1520::aid-cncr26>3.0.co;2-0", "type": "journal-article", "created": {"date-parts": [[2004, 10, 18]], "date-time": "2004-10-18T16:40:29Z", "timestamp": 1098117629000}, "page": "1520-1521", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer: Two years later"], "prefix": "10.1002", "volume": "78", "author": [{"given": "Anna A.", "family": "Kasperlik-Zaluska", "sequence": "first", "affiliation": []}, {"given": "Barbara M.", "family": "Migdalska", "sequence": "additional", "affiliation": []}, {"given": "Anna M.", "family": "Makowska", "sequence": "additional", "affiliation": []}], "member": "311", "reference": [{"key": "10.1002/(SICI)1097-0142(19961001)78:7<1520::AID-CNCR26>3.0.CO;2-0-BIB1", "author": "Carpenter", "volume": "71", "first-page": "2900", "year": "1993", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(19930515)71:10<2900::AID-CNCR2820711003>3.0.CO;2-S", "doi-asserted-by": "crossref"}, {"key": "10.1002/(SICI)1097-0142(19961001)78:7<1520::AID-CNCR26>3.0.CO;2-0-BIB2", "author": "Vassilopoulou-Sellin", "volume": "71", "first-page": "3119", "year": "1993", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(19930515)71:10<3119::AID-CNCR2820711037>3.0.CO;2-8", "doi-asserted-by": "crossref"}, {"key": "10.1002/(SICI)1097-0142(19961001)78:7<1520::AID-CNCR26>3.0.CO;2-0-BIB3", "author": "Trainer", "volume": "23", "first-page": "571", "year": "1994", "journal-title": "Endocrinol Metab Clin North Am", "DOI": "10.1016/S0889-8529(18)30085-9", "doi-asserted-by": "crossref"}, {"key": "10.1002/(SICI)1097-0142(19961001)78:7<1520::AID-CNCR26>3.0.CO;2-0-BIB4", "author": "Kasperlik-Za\u0142uska", "volume": "73", "first-page": "1533", "year": "1994", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(19940301)73:5<1533::AID-CNCR2820730536>3.0.CO;2-G", "doi-asserted-by": "crossref"}, {"key": "10.1002/(SICI)1097-0142(19961001)78:7<1520::AID-CNCR26>3.0.CO;2-0-BIB5", "author": "Kasperlik-Za\u0142uska", "volume": "75", "first-page": "2587", "year": "1995", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(19950515)75:10<2587::AID-CNCR2820751028>3.0.CO;2-5", "doi-asserted-by": "crossref"}], "container-title": ["Cancer"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F(SICI)1097-0142(19961001)78:7%3C1520::AID-CNCR26%3E3.0.CO;2-0", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/(SICI)1097-0142(19961001)78:7%3C1520::AID-CNCR26%3E3.0.CO;2-0", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 10, 2]], "date-time": "2018-10-02T02:10:29Z", "timestamp": 1538446229000}, "score": 29.261133, "issued": {"date-parts": [[1996, 10, 1]]}, "references-count": 5, "journal-issue": {"published-print": {"date-parts": [[1996, 10, 1]]}, "issue": "7"}, "URL": "http://dx.doi.org/10.1002/(sici)1097-0142(19961001)78:7<1520::aid-cncr26>3.0.co;2-0", "relation": {"cites": []}, "ISSN": ["0008-543X", "1097-0142"], "issn-type": [{"value": "0008-543X", "type": "print"}, {"value": "1097-0142", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T10:34:06Z", "timestamp": 1574850846024}, "publisher-location": "Cham", "reference-count": 93, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319624693", "type": "print"}, {"value": "9783319624709", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2017, 7, 14]], "date-time": "2017-07-14T00:00:00Z", "timestamp": 1499990400000}, "delay-in-days": 0, "content-version": "unspecified"}, {"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2017, 7, 14]], "date-time": "2017-07-14T00:00:00Z", "timestamp": 1499990400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "published-print": {"date-parts": [[2018]]}, "DOI": "10.1007/978-3-319-62470-9_13", "type": "book-chapter", "created": {"date-parts": [[2017, 10, 25]], "date-time": "2017-10-25T08:13:08Z", "timestamp": 1508919188000}, "page": "311-330", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Adrenal Cortical Carcinoma: Mitotane and Beyond"], "prefix": "10.1007", "author": [{"given": "Silvia", "family": "De Francia", "sequence": "first", "affiliation": []}, {"given": "Paola", "family": "Perotti", "sequence": "additional", "affiliation": []}, {"given": "Vittoria", "family": "Basile", "sequence": "additional", "affiliation": []}, {"given": "Antonina", "family": "Germano", "sequence": "additional", "affiliation": []}, {"given": "Massimo", "family": "Terzolo", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2017, 7, 14]]}, "reference": [{"key": "13_CR1", "doi-asserted-by": "publisher", "first-page": "711", "DOI": "10.1002/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.0.CO;2-W", "volume": "88", "author": "BL Wajchenberg", "year": "2000", "unstructured": "Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer. 2000;88:711\u201336.", "journal-title": "Cancer"}, {"key": "13_CR2", "doi-asserted-by": "publisher", "first-page": "914", "DOI": "10.1007/s00268-001-0030-7", "volume": "25", "author": "AP Dackiw", "year": "2001", "unstructured": "Dackiw AP, Lee JE, Gagel RF, et al. Adrenal cortical carcinoma. World J Surg. 2001;25:914\u201326.", "journal-title": "World J Surg"}, {"key": "13_CR3", "first-page": "273", "volume": "60", "author": "B Allolio", "year": "2006", "unstructured": "Allolio B, Fassnacht M. Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;60:273\u201387. A comprehensive review providing an excellent update on the clinical management of ACC", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR4", "doi-asserted-by": "publisher", "first-page": "2415", "DOI": "10.1056/NEJMe078087", "volume": "356", "author": "DE Schteingart", "year": "2007", "unstructured": "Schteingart DE. Adjuvant mitotane therapy of adrenal cancer: use and controversy. N Engl J Med. 2007;356:2415\u20138.", "journal-title": "N Engl J Med"}, {"key": "13_CR5", "doi-asserted-by": "publisher", "first-page": "4551", "DOI": "10.1210/jc.2013-3020", "volume": "98", "author": "M Fassnacht", "year": "2013", "unstructured": "Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4551\u201364.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR6", "doi-asserted-by": "publisher", "first-page": "1043", "DOI": "10.1677/ERC-08-0103", "volume": "15", "author": "F Daffara", "year": "2008", "unstructured": "Daffara F, De Francia S, Reimondo G, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer. 2008;15:1043\u201353.", "journal-title": "Endocr Relat Cancer"}, {"key": "13_CR7", "doi-asserted-by": "publisher", "first-page": "1197", "DOI": "10.1590/S0100-879X2000001000009", "volume": "33", "author": "DE Schteingart", "year": "2000", "unstructured": "Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Br J Med Biol Res. 2000;33:1197\u2013200.", "journal-title": "Br J Med Biol Res"}, {"key": "13_CR8", "doi-asserted-by": "publisher", "first-page": "281", "DOI": "10.1016/j.taap.2009.10.018", "volume": "242", "author": "V Asp", "year": "2010", "unstructured": "Asp V, Ulleras E, Lindstrom V, et al. Biphasic hormonal responses to the adrenocorticolytic DDT metabolite 3-methylsulfonyl-DDE in human cells. Toxicol Appl Pharmacol. 2010;242:281\u20139.", "journal-title": "Toxicol Appl Pharmacol"}, {"key": "13_CR9", "doi-asserted-by": "publisher", "first-page": "127", "DOI": "10.1016/0041-008X(73)90185-3", "volume": "24", "author": "MM Hart", "year": "1973", "unstructured": "Hart MM, Reagan RL, Adamson RH. The effect of isomers of DDD on the ACTH-induced steroid output, histology and ultrastructure of the dog adrenal cortex. Toxicol Appl Pharmacol. 1973;24:127\u201359.", "journal-title": "Toxicol Appl Pharmacol"}, {"key": "13_CR10", "doi-asserted-by": "publisher", "first-page": "14", "DOI": "10.1016/j.tox.2012.04.007", "volume": "298", "author": "CW Lin", "year": "2012", "unstructured": "Lin CW, Chang YH, Pu HF. Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells. Toxicology. 2012;298:14\u201323.", "journal-title": "Toxicology"}, {"key": "13_CR11", "doi-asserted-by": "publisher", "first-page": "730", "DOI": "10.1210/jcem-36-4-730", "volume": "36", "author": "RD Brown", "year": "1973", "unstructured": "Brown RD, Nicholson WE, Chick WT, et al. Effect of o,p\u2019DDD on human adrenal steroid 11b-hydroxylation activity. J Clin Endocrinol Metab. 1973;36:730\u20133.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR12", "doi-asserted-by": "publisher", "first-page": "443", "DOI": "10.1530/ERC-12-0217", "volume": "20", "author": "PM Koetsveld van", "year": "2013", "unstructured": "van Koetsveld PM, Vitale G, Feelders RA, et al. Interferon-b is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Endocr Relat Cancer. 2013;20:443\u201354.", "journal-title": "Endocr Relat Cancer"}, {"key": "13_CR13", "doi-asserted-by": "publisher", "first-page": "893", "DOI": "10.3892/mmr.2012.1244", "volume": "7", "author": "TP Lehmann", "year": "2013", "unstructured": "Lehmann TP, Wrzesinski T, Jagodzinski PP. The effect of mitotane on viability, steroidogenesis and gene expression in NCI-H295R adrenocortical cells. Mol Med Rep. 2013;7:893\u2013900.", "journal-title": "Mol Med Rep"}, {"key": "13_CR14", "doi-asserted-by": "publisher", "first-page": "1351", "DOI": "10.2217/pgs.12.116", "volume": "13", "author": "A Zsippai", "year": "2012", "unstructured": "Zsippai A, Szab\u00f2 DR, Tombol Z, et al. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study. Pharmacogenomics. 2012;13:1351\u201361.", "journal-title": "Pharmacogenomics"}, {"key": "13_CR15", "doi-asserted-by": "publisher", "first-page": "161", "DOI": "10.1210/jc.2012-2851", "volume": "98", "author": "V Chortis", "year": "2013", "unstructured": "Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5a-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 2013;98:161\u201371.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR16", "doi-asserted-by": "publisher", "first-page": "37", "DOI": "10.1530/EC-12-0028", "volume": "1", "author": "L Ghataore", "year": "2012", "unstructured": "Ghataore L, Chakraborti I, Aylwin SJ, et al. Effects of mitotane treatment on human steroid metabolism: implications for patient management. Endocr Connect. 2012;1:37\u201347.", "journal-title": "Endocr Connect"}, {"key": "13_CR17", "doi-asserted-by": "publisher", "first-page": "537", "DOI": "10.1530/ERC-13-0150", "volume": "20", "author": "G Poli", "year": "2013", "unstructured": "Poli G, Guasti D, Rapizzi E, et al. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer. 2013;20:537\u201350.", "journal-title": "Endocr Relat Cancer"}, {"key": "13_CR18", "doi-asserted-by": "publisher", "first-page": "371", "DOI": "10.1530/ERC-12-0368", "volume": "20", "author": "S Hescot", "year": "2013", "unstructured": "Hescot S, Slama A, Lomb\u00e8s A, et al. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer. 2013;20:371\u201381.", "journal-title": "Endocr Relat Cancer"}, {"key": "13_CR19", "doi-asserted-by": "publisher", "first-page": "3895", "DOI": "10.1210/en.2015-1367", "volume": "156", "author": "S Sbiera", "year": "2015", "unstructured": "Sbiera S, Leich E, Liebisch G, et al. Mitotane inhibits sterol-o-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 2015;156:3895\u2013908.", "journal-title": "Endocrinology"}, {"key": "13_CR20", "doi-asserted-by": "publisher", "first-page": "47", "DOI": "10.1016/0041-008X(85)90266-2", "volume": "77", "author": "RC Pohland", "year": "1985", "unstructured": "Pohland RC, Counsell RE. The role of high density lipoproteins in the biodistribution of two radioiodinated probes in the rat. Toxicol Appl Pharmacol. 1985;77:47\u201357.", "journal-title": "Toxicol Appl Pharmacol"}, {"key": "13_CR21", "doi-asserted-by": "publisher", "first-page": "261", "DOI": "10.1530/EJE-11-0557", "volume": "166", "author": "S Maucl\u00e8re-Denost", "year": "2012", "unstructured": "Maucl\u00e8re-Denost S, Leboulleux S, Borget I, et al. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol. 2012;166:261\u20138.", "journal-title": "Eur J Endocrinol"}, {"key": "13_CR22", "doi-asserted-by": "publisher", "first-page": "2890", "DOI": "10.1210/JC.2015-2080", "volume": "100", "author": "S Hescot", "year": "2015", "unstructured": "Hescot S, Seck A, Guerin M, et al. Lipoprotein-free mitotane exerts high cytotoxic activity in adrenocortical carcinoma. J Clin Endocrinol Metab. 2015;100:2890\u20138.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR23", "first-page": "150135", "volume": "2016", "author": "A Paci", "year": "2016", "unstructured": "Paci A, Hescot S, Seck A, et al. Dyslipidemia causes overestimation of plasma mitotane measurements. Endocrinol Diab and Metab. 2016;2016:150135.", "journal-title": "Endocrinol Diab and Metab"}, {"key": "13_CR24", "doi-asserted-by": "publisher", "first-page": "343", "DOI": "10.1530/EJE-15-0946", "volume": "174", "author": "M Kroiss", "year": "2016", "unstructured": "Kroiss M, Plonn\u00e9 D, Kendl S, et al. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. Eur J Endocrinol. 2016;174:343\u201353.", "journal-title": "Eur J Endocrinol"}, {"key": "13_CR25", "doi-asserted-by": "publisher", "first-page": "1212", "DOI": "10.1016/S0039-6060(97)90229-4", "volume": "122", "author": "R Bellantone", "year": "1997", "unstructured": "Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997;122:1212\u20138.", "journal-title": "Surgery"}, {"key": "13_CR26", "doi-asserted-by": "publisher", "first-page": "891", "DOI": "10.1007/s00268-001-0047-y", "volume": "25", "author": "P Icard", "year": "2001", "unstructured": "Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25:891\u20137.", "journal-title": "World J Surg"}, {"key": "13_CR27", "doi-asserted-by": "publisher", "first-page": "719", "DOI": "10.1007/s10434-999-0719-7", "volume": "6", "author": "RD Schulick", "year": "1999", "unstructured": "Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6:719\u201326.", "journal-title": "Ann Surg Oncol"}, {"key": "13_CR28", "first-page": "963", "volume": "112", "author": "RF Pommier", "year": "1992", "unstructured": "Pommier RF, Brennan MF. An 11-year experience with adrenocortical carcinoma. Surgery. 1992;112:963\u201370.", "journal-title": "Surgery"}, {"key": "13_CR29", "doi-asserted-by": "publisher", "first-page": "1142", "DOI": "10.1001/archsurg.1982.01380330010004", "volume": "117", "author": "DE Schteingart", "year": "1982", "unstructured": "Schteingart DE, Motazedi A, Noonan RA, Thompson NW. Treatment of adrenal carcinomas. Arch Surg. 1982;117:1142\u20136.", "journal-title": "Arch Surg"}, {"key": "13_CR30", "doi-asserted-by": "publisher", "first-page": "765", "DOI": "10.1002/1097-0142(19890801)64:3<765::AID-CNCR2820640333>3.0.CO;2-I", "volume": "64", "author": "S Venkatesh", "year": "1989", "unstructured": "Venkatesh S, Hickey RC, Sellin RV, et al. Adrenal cortical carcinoma. Cancer. 1989;64:765\u20139.", "journal-title": "Cancer"}, {"key": "13_CR31", "doi-asserted-by": "publisher", "first-page": "941", "DOI": "10.1200/JCO.2002.20.4.941", "volume": "20", "author": "A Stojadinovic", "year": "2002", "unstructured": "Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20:941\u201350.", "journal-title": "J Clin Oncol"}, {"key": "13_CR32", "doi-asserted-by": "publisher", "first-page": "2650", "DOI": "10.1210/jc.2005-2730", "volume": "91", "author": "G Abiven", "year": "2006", "unstructured": "Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91:2650\u20135.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR33", "doi-asserted-by": "publisher", "first-page": "257", "DOI": "10.1016/S0022-5347(17)40734-8", "volume": "141", "author": "B Bodie", "year": "1989", "unstructured": "Bodie B, Novick AC, Pontes JE, et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol. 1989;141:257\u201360.", "journal-title": "J Urol"}, {"key": "13_CR34", "doi-asserted-by": "publisher", "first-page": "3119", "DOI": "10.1002/1097-0142(19930515)71:10<3119::AID-CNCR2820711037>3.0.CO;2-8", "volume": "71", "author": "R Vassilopoulou-Sellin", "year": "1993", "unstructured": "Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1993;71:3119\u201323.", "journal-title": "Cancer"}, {"key": "13_CR35", "doi-asserted-by": "publisher", "first-page": "947", "DOI": "10.1038/bjc.1994.183", "volume": "69", "author": "HR Haak", "year": "1994", "unstructured": "Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994;69:947\u201351.", "journal-title": "Br J Cancer"}, {"key": "13_CR36", "doi-asserted-by": "publisher", "first-page": "490", "DOI": "10.1159/000227608", "volume": "54", "author": "L Barzon", "year": "1997", "unstructured": "Barzon L, Fallo F, Sonino N, et al. Adrenocortical carcinoma: experience in 45 patients. Oncology. 1997;54:490\u20136.", "journal-title": "Oncology"}, {"key": "13_CR37", "first-page": "3100", "volume": "83", "author": "G Dickstein", "year": "1998", "unstructured": "Dickstein G, Shechner C, Arad E, et al. Is there a role for low doses of mitotane (o,p 0 -DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab. 1998;83:3100\u20133.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR38", "doi-asserted-by": "publisher", "first-page": "1191", "DOI": "10.1590/S0100-879X2000001000008", "volume": "33", "author": "AA Kasperlik-Zaluska", "year": "2000", "unstructured": "Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res. 2000;33:1191\u20136.", "journal-title": "Braz J Med Biol Res"}, {"key": "13_CR39", "doi-asserted-by": "publisher", "first-page": "1385", "DOI": "10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2", "volume": "92", "author": "E Baudin", "year": "2001", "unstructured": "Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1, 1-dichlorodiphenildichloroethane (o,p 0 -DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001;92:1385\u201392.", "journal-title": "Cancer"}, {"key": "13_CR40", "doi-asserted-by": "publisher", "first-page": "2372", "DOI": "10.1056/NEJMoa063360", "volume": "356", "author": "M Terzolo", "year": "2007", "unstructured": "Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372\u201380.", "journal-title": "N Engl J Med"}, {"key": "13_CR41", "doi-asserted-by": "publisher", "first-page": "263", "DOI": "10.1245/s10434-009-0716-x", "volume": "17", "author": "EG Grubbs", "year": "2010", "unstructured": "Grubbs EG, Callender GG, Yan Xing Y, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010;17:263\u201370.", "journal-title": "Ann Surg Oncol"}, {"key": "13_CR42", "doi-asserted-by": "publisher", "first-page": "4925", "DOI": "10.1210/jc.2010-0803", "volume": "95", "author": "M Fassnacht", "year": "2010", "unstructured": "Fassnacht M, Johanssen S, Fenske W, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010;95:4925\u201332.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR43", "doi-asserted-by": "publisher", "first-page": "265", "DOI": "10.1677/ERC-09-0190", "volume": "17", "author": "B W\u00e4ngberg", "year": "2010", "unstructured": "W\u00e4ngberg B, Khorram-Manesh A, Jansson S, et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer. 2010;17:265\u201372.", "journal-title": "Endocr Relat Cancer"}, {"key": "13_CR44", "doi-asserted-by": "publisher", "first-page": "455", "DOI": "10.1210/jc.2013-2856", "volume": "99", "author": "T Else", "year": "2014", "unstructured": "Else T, Williams AR, Sabolch A, et al. Adjuvant therapies, patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99:455\u201361.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR45", "doi-asserted-by": "publisher", "first-page": "2587", "DOI": "10.1002/1097-0142(19950515)75:10<2587::AID-CNCR2820751028>3.0.CO;2-5", "volume": "75", "author": "AA Kasperlik-Zaluska", "year": "1995", "unstructured": "Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, et al. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer. 1995;75:2587\u201391.", "journal-title": "Cancer"}, {"key": "13_CR46", "first-page": "972", "volume": "112", "author": "P Icard", "year": "1992", "unstructured": "Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery. 1992;112:972\u20139.", "journal-title": "Surgery"}, {"key": "13_CR47", "doi-asserted-by": "publisher", "first-page": "667", "DOI": "10.1677/erc.1.01029", "volume": "12", "author": "DE Schteingart", "year": "2005", "unstructured": "Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12:667\u201380.", "journal-title": "Endocr Relat Cancer"}, {"key": "13_CR48", "doi-asserted-by": "publisher", "first-page": "1256", "DOI": "10.1056/NEJMc076267", "volume": "357", "author": "J Bertherat", "year": "2007", "unstructured": "Bertherat J, Coste J, Bertagna X. Adjuvant mitotane in adrenocortical carcinoma [letter to the editor]. N Engl J Med. 2007;357:1256\u20139.", "journal-title": "N Engl J Med"}, {"key": "13_CR49", "doi-asserted-by": "publisher", "first-page": "832", "DOI": "10.1016/j.eururo.2013.11.006", "volume": "65", "author": "A Berruti", "year": "2014", "unstructured": "Berruti A, Fassnacht M, Haak H, et al. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol. 2014;65:832\u20138.", "journal-title": "Eur Urol"}, {"key": "13_CR50", "doi-asserted-by": "publisher", "first-page": "3730", "DOI": "10.1210/jc.2008-0579", "volume": "93", "author": "H Huang", "year": "2008", "unstructured": "Huang H, Fojo T. Adjuvant mitotane for adrenocortical cancer a recurring controversy. J Clin Endocrinol Metab. 2008;93:3730\u20132.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR51", "doi-asserted-by": "publisher", "first-page": "4619", "DOI": "10.1200/JCO.2008.17.2775", "volume": "27", "author": "I Veytsman", "year": "2009", "unstructured": "Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27:4619\u201329.", "journal-title": "J Clin Oncol"}, {"key": "13_CR52", "doi-asserted-by": "publisher", "first-page": "263", "DOI": "10.1530/EJE-13-0242", "volume": "169", "author": "M Terzolo", "year": "2013", "unstructured": "Terzolo M, Baudin AE, Ardito A, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol. 2013;169:263\u201370.", "journal-title": "Eur J Endocrinol"}, {"key": "13_CR53", "doi-asserted-by": "publisher", "first-page": "1844", "DOI": "10.1210/jc.2010-2676", "volume": "96", "author": "IG Hermsen", "year": "2011", "unstructured": "Hermsen IG, Fassnacht M, Terzolo M, et al. Plasma concentrations of o,p\u2019DDD, o,p\u2019DDA, and o,p\u2019DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab. 2011;96:1844\u201351.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR54", "doi-asserted-by": "publisher", "first-page": "221", "DOI": "10.1097/MED.0b013e3282fdf4c0", "volume": "15", "author": "M Terzolo", "year": "2008", "unstructured": "Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes. 2008;15:221\u20136.", "journal-title": "Curr Opin Endocrinol Diabetes Obes"}, {"key": "13_CR55", "doi-asserted-by": "publisher", "first-page": "521", "DOI": "10.1007/s12020-012-9719-7", "volume": "42", "author": "M Terzolo", "year": "2012", "unstructured": "Terzolo M, Ardito A, Zaggia B, et al. Management of adjuvant mitotane therapy following resection of adrenal cancer. Endocrine. 2012;42:521\u20135.", "journal-title": "Endocrine"}, {"key": "13_CR56", "doi-asserted-by": "publisher", "first-page": "e401", "DOI": "10.1200/JCO.2009.27.5958", "volume": "28", "author": "A Berruti", "year": "2010", "unstructured": "Berruti A, Fassnacht M, Baudin E, et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol. 2010;28:e401\u20132.", "journal-title": "J Clin Oncol"}, {"key": "13_CR57", "doi-asserted-by": "publisher", "first-page": "323", "DOI": "10.1038/nrendo.2010.235", "volume": "7", "author": "M Fassnacht", "year": "2011", "unstructured": "Fassnacht M, Lib\u00e9 R, Kroiss M, et al. Adrenocortical carcinoma: a clinician\u2019s update. Nat Rev Endocrinol. 2011;7:323\u201335.", "journal-title": "Nat Rev Endocrinol"}, {"key": "13_CR58", "doi-asserted-by": "publisher", "first-page": "535", "DOI": "10.1111/j.1365-2559.2009.03423.x", "volume": "55", "author": "M Volante", "year": "2009", "unstructured": "Volante M, Bollito E, Sperone P, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology. 2009;55:535\u201343.", "journal-title": "Histopathology"}, {"key": "13_CR59", "doi-asserted-by": "publisher", "first-page": "1256", "DOI": "10.1056/NEJMc076267", "volume": "357", "author": "G Dickstein", "year": "2007", "unstructured": "Dickstein G, Shechner C, Natif O. Adjuvant mitotane in adrenocortical carcinoma. letter to the editor. N Engl J Med. 2007;357:1256\u20137.", "journal-title": "N Engl J Med"}, {"key": "13_CR60", "doi-asserted-by": "publisher", "first-page": "110", "DOI": "10.1111/j.1365-2265.2005.02403.x", "volume": "64", "author": "A Faggiano", "year": "2006", "unstructured": "Faggiano A, Leboulleux S, Young J, et al. Rapidly progressing high o,p\u2019-DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol. 2006;64:110\u20133. A study reporting feasibility of a high-dose regimen of mitotane", "journal-title": "Clin Endocrinol"}, {"key": "13_CR61", "doi-asserted-by": "publisher", "first-page": "1043", "DOI": "10.1677/ERC-08-0103", "volume": "4", "author": "F Daffara", "year": "2008", "unstructured": "Daffara F, De Francia S, Reimondo G, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer. 2008;4:1043\u201353.", "journal-title": "Endocr Relat Cancer"}, {"key": "13_CR62", "doi-asserted-by": "publisher", "first-page": "51", "DOI": "10.1111/j.1365-2265.1989.tb00453.x", "volume": "31", "author": "RV Hague", "year": "1989", "unstructured": "Hague RV, May W, Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o,p\u2019-DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol. 1989;31:51\u20137.", "journal-title": "Clin Endocrinol"}, {"key": "13_CR63", "doi-asserted-by": "publisher", "first-page": "2165", "DOI": "10.1210/jc.2005-2157", "volume": "91", "author": "N Nancy Nader", "year": "2006", "unstructured": "Nancy Nader N, Raverot G, Emptoz-Bonneton A, et al. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab. 2006;91:2165\u201370. A study demonstrating an oestrogen-like effect of mitotane", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR64", "doi-asserted-by": "publisher", "first-page": "243", "DOI": "10.1002/cncr.24030", "volume": "115", "author": "M Fassnacht", "year": "2009", "unstructured": "Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115:243\u201350.", "journal-title": "Cancer"}, {"key": "13_CR65", "first-page": "23", "volume": "34", "author": "F Beuschlein", "year": "2013", "unstructured": "Beuschlein F, Obracay J, Saeger W, et al. Prognostic value of histological markers in localized adrenocortical carcinoma after complete resection. Endocr Rev. 2013;34:23\u20139.", "journal-title": "Endocr Rev"}, {"key": "13_CR66", "doi-asserted-by": "publisher", "first-page": "333", "DOI": "10.1007/s12672-011-0088-0", "volume": "2", "author": "M Papotti", "year": "2011", "unstructured": "Papotti M, Libe R, Duregon E, et al. The Weiss score and beyond-histopathology for adrenocortical carcinoma. Horm Cancer. 2011;2:333\u201340.", "journal-title": "Horm Cancer"}, {"key": "13_CR67", "doi-asserted-by": "publisher", "first-page": "192", "DOI": "10.1097/MED.0b013e3283602274", "volume": "20", "author": "I Bourdeau", "year": "2013", "unstructured": "Bourdeau I, Mackenzie-Feder J, Lacroix A. Recent advances in adrenocortical carcinoma in adults. Curr Opin Endocrinol Diabetes Obes. 2013;20:192\u20137.", "journal-title": "Curr Opin Endocrinol Diabetes Obes"}, {"key": "13_CR68", "doi-asserted-by": "publisher", "first-page": "872", "DOI": "10.1007/s00268-005-0329-x", "volume": "30", "author": "E Kebebew", "year": "2006", "unstructured": "Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872\u20138.", "journal-title": "World J Surg"}, {"key": "13_CR69", "doi-asserted-by": "publisher", "first-page": "2579", "DOI": "10.1016/j.ejca.2013.02.034", "volume": "49", "author": "TM Kerkhofs", "year": "2013", "unstructured": "Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: a population based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49:2579\u201386.", "journal-title": "Eur J Cancer"}, {"issue": "Suppl 7", "key": "13_CR70", "doi-asserted-by": "publisher", "first-page": "VII131", "DOI": "10.1093/annonc/mds231", "volume": "23", "author": "A Berruti", "year": "2012", "unstructured": "Berruti A, Baudin E, Gelderblom H, et al. Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. Ann Oncol. 2012;23(Suppl 7):VII131\u20138.", "journal-title": "Ann Oncol"}, {"key": "13_CR71", "doi-asserted-by": "publisher", "first-page": "201", "DOI": "10.1007/s00423-011-0866-8", "volume": "397", "author": "CP Lombardi", "year": "2012", "unstructured": "Lombardi CP, Raffaelli M, Boniardi M, et al. Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbeck's Arch Surg. 2012;397:201\u20137.", "journal-title": "Langenbeck's Arch Surg"}, {"key": "13_CR72", "doi-asserted-by": "publisher", "first-page": "3130", "DOI": "10.1002/cncr.23886", "volume": "113", "author": "KY Bilimoria", "year": "2008", "unstructured": "Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130\u20136.", "journal-title": "Cancer"}, {"key": "13_CR73", "doi-asserted-by": "publisher", "first-page": "1563", "DOI": "10.1038/modpathol.3800683", "volume": "19", "author": "M Volante", "year": "2006", "unstructured": "Volante M, Sperone P, Bollito E, et al. Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Mod Pathol. 2006;19:1563\u20139.", "journal-title": "Mod Pathol"}, {"key": "13_CR74", "doi-asserted-by": "publisher", "first-page": "919", "DOI": "10.1677/ERC-08-0211", "volume": "16", "author": "W Fenske", "year": "2009", "unstructured": "Fenske W, Volker HU, Adam P, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer. 2009;16:919\u201328.", "journal-title": "Endocr Relat Cancer"}, {"key": "13_CR75", "doi-asserted-by": "publisher", "first-page": "822", "DOI": "10.1016/j.humpath.2012.07.025", "volume": "44", "author": "E Duregon", "year": "2013", "unstructured": "Duregon E, Volante M, Giorcelli J, et al. Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Hum Pathol. 2013;44:822\u20138.", "journal-title": "Hum Pathol"}, {"key": "13_CR76", "doi-asserted-by": "publisher", "first-page": "1108", "DOI": "10.1200/JCO.2008.18.5678", "volume": "27", "author": "A Reynies De", "year": "2009", "unstructured": "De Reynies A, Assie G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 2009;27:1108\u201315.", "journal-title": "J Clin Oncol"}, {"key": "13_CR77", "doi-asserted-by": "publisher", "first-page": "3452", "DOI": "10.1158/1078-0432.CCR-11-2692", "volume": "18", "author": "M Volante", "year": "2012", "unstructured": "Volante M, Terzolo M, Fassnacht M, et al. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer. Clin Cancer Res. 2012;18:3452\u201361.", "journal-title": "Clin Cancer Res"}, {"key": "13_CR78", "doi-asserted-by": "publisher", "first-page": "797", "DOI": "10.1677/ERC-09-0341", "volume": "17", "author": "P Malandrino", "year": "2010", "unstructured": "Malandrino P, Al Ghuzlan A, Castaing M, et al. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer. 2010;17:797\u2013807.", "journal-title": "Endocr Relat Cancer"}, {"key": "13_CR79", "doi-asserted-by": "publisher", "first-page": "148", "DOI": "10.1210/jc.2006-0706", "volume": "92", "author": "G Assi\u00e9", "year": "2007", "unstructured": "Assi\u00e9 G, Antoni G, Tissier F, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2007;92:148\u201354.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR80", "doi-asserted-by": "publisher", "first-page": "657", "DOI": "10.1677/erc.1.01025", "volume": "12", "author": "A Berruti", "year": "2005", "unstructured": "Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12:657\u201366.", "journal-title": "Endocr Relat Cancer"}, {"key": "13_CR81", "doi-asserted-by": "publisher", "first-page": "1527", "DOI": "10.1016/j.jvir.2010.05.020", "volume": "21", "author": "J Cazejust", "year": "2010", "unstructured": "Cazejust J, De Ba\u00e8re T, Auperin A, et al. Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol. 2010;21:1527\u201332.", "journal-title": "J Vasc Interv Radiol"}, {"key": "13_CR82", "doi-asserted-by": "publisher", "first-page": "18", "DOI": "10.1210/jcem-73-1-18", "volume": "73", "author": "SE Bates", "year": "1991", "unstructured": "Bates SE, Shieh CY, Mickley LA, et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab. 1991;73:18\u201329.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "13_CR83", "first-page": "926", "volume": "94", "author": "DJ Henley", "year": "1983", "unstructured": "Henley DJ, van Heerden JA, Grant CS, et al. Adrenal cortical carcinoma\u2013\u2013a continuing challenge. Surgery. 1983;94:926\u201331.", "journal-title": "Surgery"}, {"key": "13_CR84", "doi-asserted-by": "publisher", "first-page": "1195", "DOI": "10.1056/NEJM199004263221705", "volume": "322", "author": "JP Luton", "year": "1990", "unstructured": "Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322:1195\u2013201.", "journal-title": "N Engl J Med"}, {"key": "13_CR85", "doi-asserted-by": "publisher", "first-page": "1159", "DOI": "10.1002/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R", "volume": "88", "author": "SK Williamson", "year": "2000", "unstructured": "Williamson SK, Lew D, Miller GJ, et al. Phase II evaluation of cisplatin and etopo-side followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer. 2000;88:1159\u201365.", "journal-title": "Cancer"}, {"key": "13_CR86", "first-page": "1006", "volume": "110", "author": "RA Decker", "year": "1991", "unstructured": "Decker RA, Elson P, Hogan TF, et al. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery. 1991;110:1006\u201313.", "journal-title": "Surgery"}, {"key": "13_CR87", "first-page": "133", "volume": "14", "author": "R Villa", "year": "1999", "unstructured": "Villa R, Orlandi L, Berruti A, et al. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int J Oncol. 1999;14:133\u20138.", "journal-title": "Int J Oncol"}, {"key": "13_CR88", "doi-asserted-by": "publisher", "first-page": "2194", "DOI": "10.1002/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3", "volume": "83", "author": "A Berruti", "year": "1998", "unstructured": "Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer. 1998;83:2194\u2013200.", "journal-title": "Cancer"}, {"key": "13_CR89", "doi-asserted-by": "publisher", "first-page": "207", "DOI": "10.1007/s40618-013-0049-2", "volume": "37", "author": "M Terzolo", "year": "2014", "unstructured": "Terzolo M, Daffara F, Ardito A, et al. Management of adrenal cancer: a 2013 update. J Endocrinol Investig. 2014;37:207\u201317.", "journal-title": "J Endocrinol Investig"}, {"key": "13_CR90", "doi-asserted-by": "publisher", "first-page": "2189", "DOI": "10.1056/NEJMoa1200966", "volume": "366", "author": "M Fassnacht", "year": "2012", "unstructured": "Fassnacht M, Terzolo M, Allolio B, et al. FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189\u201397.", "journal-title": "N Engl J Med"}, {"key": "13_CR91", "doi-asserted-by": "publisher", "first-page": "445", "DOI": "10.1007/s12020-011-9502-1", "volume": "40", "author": "YZ Xu", "year": "2011", "unstructured": "Xu YZ, Zhu Y, Shen ZJ, et al. Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine. 2011;40:445\u201351.", "journal-title": "Endocrine"}, {"key": "13_CR92", "doi-asserted-by": "publisher", "first-page": "479", "DOI": "10.1007/s12020-012-9593-3", "volume": "41", "author": "J Ye", "year": "2012", "unstructured": "Ye J, Qi Y, Wang W, et al. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas. Endocrine. 2012;41:479\u201386.", "journal-title": "Endocrine"}, {"key": "13_CR93", "doi-asserted-by": "publisher", "first-page": "554", "DOI": "10.1002/cncr.11084", "volume": "97", "author": "BJ Wood", "year": "2003", "unstructured": "Wood BJ, Abraham J, Hvizda JL, et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinomametastases. Cancer. 2003;97:554\u201360.", "journal-title": "Cancer"}], "container-title": ["Contemporary Endocrinology", "Adrenal Disorders"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-62470-9_13", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 20]], "date-time": "2019-05-20T22:11:09Z", "timestamp": 1558390269000}, "score": 28.979393, "issued": {"date-parts": [[2017, 7, 14]]}, "ISBN": ["9783319624693", "9783319624709"], "references-count": 93, "URL": "http://dx.doi.org/10.1007/978-3-319-62470-9_13", "relation": {"cites": []}, "ISSN": ["2523-3785", "2523-3793"], "issn-type": [{"value": "2523-3785", "type": "print"}, {"value": "2523-3793", "type": "electronic"}], "assertion": [{"value": "14 July 2017", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ChapterHistory", "label": "Chapter History"}}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T12:54:23Z", "timestamp": 1574859263933}, "reference-count": 0, "publisher": "Bioscientifica", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["EJEA"], "DOI": "10.1530/endoabs.49.ep161", "type": "journal-article", "created": {"date-parts": [[2017, 11, 16]], "date-time": "2017-11-16T05:46:57Z", "timestamp": 1510811217000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["CYP2W1*6 polymorphism as a potential predictive marker of sensitivity to mitotane treatment in adrenocortical carcinoma."], "prefix": "10.1530", "author": [{"given": "Barbara", "family": "Altieri", "sequence": "first", "affiliation": []}, {"given": "Sabine", "family": "Herterich", "sequence": "additional", "affiliation": []}, {"given": "Silviu", "family": "Sbiera", "sequence": "additional", "affiliation": []}, {"given": "Marco", "family": "Volante", "sequence": "additional", "affiliation": []}, {"given": "Matthias", "family": "Kroiss", "sequence": "additional", "affiliation": []}, {"given": "Silvia Della", "family": "Casa", "sequence": "additional", "affiliation": []}, {"given": "Alfredo", "family": "Pontecorvi", "sequence": "additional", "affiliation": []}, {"given": "Massimo", "family": "Terzolo", "sequence": "additional", "affiliation": []}, {"given": "Martin", "family": "Fassnacht", "sequence": "additional", "affiliation": []}, {"given": "Cristina L.", "family": "Ronchi", "sequence": "additional", "affiliation": []}], "member": "416", "published-online": {"date-parts": [[2017, 5, 3]]}, "container-title": ["Endocrine Abstracts"], "deposited": {"date-parts": [[2017, 11, 16]], "date-time": "2017-11-16T05:53:28Z", "timestamp": 1510811608000}, "score": 28.654217, "issued": {"date-parts": [[2017, 5, 3]]}, "references-count": 0, "URL": "http://dx.doi.org/10.1530/endoabs.49.ep161", "ISSN": ["1479-6848"], "issn-type": [{"value": "1479-6848", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T04:54:58Z", "timestamp": 1575176098549}, "reference-count": 0, "publisher": "Bioscientifica", "issue": "3", "content-domain": {"domain": ["erc.bioscientifica.com"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2005, 9]]}, "abstract": "<jats:p>To investigate the activity of etoposide, doxorubicin, and cisplatin plus mitotane in the management of advanced adrenocortical carcinoma (ACC) patients, 72 patients with measurable disease not amenable to radical surgery were enrolled in a prospective, multicenter phase II trial. EDP schedule (etoposide 100 mg/m<jats:sup>2</jats:sup> on days 5\u20137, doxorubicin 20 mg/m<jats:sup>2</jats:sup> on days 1 and 8, and cisplatin 40 mg/m<jats:sup>2</jats:sup> on days 1 and 9) was administered intravenously every 4 weeks. Concomitantly, patients were given up to 4 g/day of oral mitotane. Five patients achieved a complete response and 30 a partial response, for an overall response rate of 48.6% (95% CI: 37.1\u201360.3). Median time to progression in responding patients was 18 months. The EDP regimen was well tolerated, leukopenia being the dose limiting toxicity. One toxic related death due to septic shock, however, was registered. Radical surgical resection of residual disease after chemotherapy was performed in 10 patients. The overall survival of patients attaining a disease free status (clinical complete responders+radically resected) was significantly higher than that of patients with partial response or no response (<jats:italic>P</jats:italic>&lt;0.002). Androgen secretion was associated with long survival, while glucocorticoid secretion was associated with poor prognosis both in univariate and multivariate analysis. In conclusion, EDP plus mitotane is an active and manageable combination scheme for ACC patients. Surgical resection of residual disease subsequent to chemotherapy leads to a more favourable outcome. The natural history of the disease is significantly influenced by the secretory status of the tumor.</jats:p>", "DOI": "10.1677/erc.1.01025", "type": "journal-article", "created": {"date-parts": [[2005, 9, 19]], "date-time": "2005-09-19T16:42:55Z", "timestamp": 1127148175000}, "page": "657-666", "update-policy": "http://dx.doi.org/10.1530/crossmarkpolicy-1", "source": "Crossref", "is-referenced-by-count": 149, "title": ["Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial"], "prefix": "10.1530", "volume": "12", "author": [{"given": "Alfredo", "family": "Berruti", "sequence": "first", "affiliation": []}, {"given": "Massimo", "family": "Terzolo", "sequence": "additional", "affiliation": []}, {"given": "Paola", "family": "Sperone", "sequence": "additional", "affiliation": []}, {"given": "Anna", "family": "Pia", "sequence": "additional", "affiliation": []}, {"given": "Silvia", "family": "Della Casa", "sequence": "additional", "affiliation": []}, {"given": "David J", "family": "Gross", "sequence": "additional", "affiliation": []}, {"given": "Carlo", "family": "Carnaghi", "sequence": "additional", "affiliation": []}, {"given": "Paolo", "family": "Casali", "sequence": "additional", "affiliation": []}, {"given": "Francesco", "family": "Porpiglia", "sequence": "additional", "affiliation": []}, {"given": "Franco", "family": "Mantero", "sequence": "additional", "affiliation": []}, {"given": "Giuseppe", "family": "Reimondo", "sequence": "additional", "affiliation": []}, {"given": "Alberto", "family": "Angeli", "sequence": "additional", "affiliation": []}, {"given": "Luigi", "family": "Dogliotti", "sequence": "additional", "affiliation": []}], "member": "416", "container-title": ["Endocrine-Related Cancer"], "link": [{"URL": "https://erc.bioscientifica.com/view/journals/erc/12/3/0120657.xml", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 8, 28]], "date-time": "2018-08-28T05:36:21Z", "timestamp": 1535434581000}, "score": 28.654217, "issued": {"date-parts": [[2005, 9]]}, "references-count": 0, "journal-issue": {"issue": "3"}, "URL": "http://dx.doi.org/10.1677/erc.1.01025", "ISSN": ["1351-0088", "1479-6821"], "issn-type": [{"value": "1351-0088", "type": "print"}, {"value": "1479-6821", "type": "electronic"}], "subject": ["Cancer Research", "Oncology", "Endocrinology, Diabetes and Metabolism", "Endocrinology"]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}